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ABSTRACT 
DETECTION OF HUMAN PAPILLOMAVIRUS BY NUCLEIC ACID HYBRIDIZATION 
AS AN ADJUNCT TO THE PAPANICOLAOU SMEAR 
JULIA ANN SCHILLINGER 
1990 
We compared methods for detecting Human 
Papillomavirus [HPV] deoxyribonucleic acid [DNA] in cervical 
cytology specimens. Endocervical swabs were obtained from 40 
women referred to a Gynecologic oncology clinic for a 
previously abnormal Papanicolaou [Pap] smear. We employed a 
modified filter in situ method [ViraPap] for the detection of 
HPV DNA, followed by HPV typing [ViraType]. Sixteen of 40 
specimens were positive for the presence of HPV DNA by 
hybridization with probes specific to HPV of types 6, 11, 16, 
18, 31, 33, and 35. Of these, 5 patients had negative Pap 
smears but evidence of disease by other parameters 
(endocervical curettage [ECC], cervical biopsy [CBx], 
colposcopy) . Four of these 5 patients with negative Pap 
smears were infected with a type of HPV associated with a high 
risk of developing cervical disease; types 16/18. 7 patients 
had positive Pap smears with evidence of disease on cervical 
biopsy, but had negative ViraPap results. We then used the 

polymerase chain reaction [PCR] to amplify segments of the 
HPV-16 E6 and E7 open reading frames [ORFs] . The E6 ORF was 
found to be the most sensitive. In three independent PCR 
assays, 13 specimens contained the HPV-16 E6 DNA. These 
included all of those typed as 16/18 by the ViraType method 
as well as 5 additional samples not detected by the 
hybridization methods; 3 with abnormal Pap smears, and 2 with 
normal Pap smears but evidence of disease by CBx. We conclude 
that in a population at high risk for cervical disease, the 
ViraPap can be a useful adjunct to the Pap smear in the 
detection of disease and that PCR of the HPV-16 E6 ORF may be 
used as a sensitive, but more labor intensive, confirmatory 
test. 
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1 
INTRODUCTION 
In 1989, 6,000 women died of cervical cancer, and 13,000 
new cases of invasive cervical cancer were diagnosed (43). 
Many studies have established a strong association between 
infection with the Human Papillomavirus (HPV) and the 
development of cervical cancer and its' precursor lesions (10, 
14, 15, 16, 18, 33, 36, 38, 57, 65, 83); over 90% of cervical 
cancers examined have been found to contain HPV DNA seguences 
integrated into the host cell genome (38, 64). There has been 
tremendous interest and attention focussed on the Human 
Papillomavirus in recent years as a model for viral 
oncogenesis. To date more than 60 different types of HPV have 
been identified. The various types show an apparent cellular 
tropism, with twenty-three preferentially infecting the 
genital tract. Among these types there appears to be a range 
of oncogenic potential. 
Current understanding of the biological behavior of 
cervical cancer suggests that these malignancies are the most 
severe in a range of precursor lesions usually described as 
cervical dysplasias. Because the prognosis for a woman with 
cervical cancer is determined by the stage at which the 
disease is detected, early diagnosis is the best means of 
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reducing mortality. The Papanicolaou (Pap) smear has been 
extremely effective in identifying occult carcinomas and 
premalignant lesions of the cervix, and the mortality and 
morbidity associated with cervical cancer have decreased 
dramatically in the past 40 years. Nonetheless, a percentage 
of invasive cancers and its precursor lesions go undetected 
by Pap smears each year. HPV is notorious for confounding the 
interpretation of Pap smears, blurring the distinction between 
non-neoplastic proliferative processes and preneoplastic 
changes, and contributing to ambiguity in the grading of 
lesions. Increasing recognition of the prevalence of HPV 
infection in the general population has spurred an interest 
in a more reliable means of detection. 
In 1989 the Food and Drug Administration licensed a test 
kit for the detection of HPV in endocervical swabs and 
cervical biopsy specimens. This test, known as ViraPap and 
manufactured by Bethesda Research Laboratories, utilizes 
filter hybridization techniques to detect virus in processed 
specimens. The ViraPap test uses P labelled probes composed 
of RNA sequences complementary to the DNA of HPV types 6, 11, 
16, 18, 31, 33, and 35; the seven types most frequently found 
to infect the genital tract. 
This study was designed to assess the clinical usefulness 
of detecting HPV in specimens of exfoliated cervical cells. 
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Because screening and diagnostic tests already exist for 
recognition of the morphologic changes leading to cervical 
cancer, the usefulness would have to hinge on the tests' 
ability to provide information the alternative methods could 
not. In this study the detection of HPV in an endocervical 
swab specimen by hybridization technigue was compared to the 
results of concurrently taken Pap smears, biopsies, and 
colposcopy in 40 patients. Because of the apparent range in 
the oncogenic potential of different HPV types, typing was 
undertaken on all the specimens shown to contain HPV DNA. 
Specimens shown to contain HPV DNA of type 16 were confirmed 
by use of the polymerase chain reaction, a highly sensitive 
means of DNA amplification. 
An assessment of a diagnostic test reguires an in depth 
understanding of the phenomenon being examined, as well as an 
appreciation for how the proposed test adds to or complements 
the existing methodology. With these ends in mind, this paper 
will first address the current understanding of the Human 
Papillomavirus and its proposed relation to cervical cancer, 
and then will review the uses and limitations of existing 
screening and diagnostic tests, with particular attention to 
the Pap smear and hybridization technique. 
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The Human Papillomavirus 
The Human Papillomavirus is one of the genus 
Papillomavirus, belonging to the family of viruses known as 
Papovaviridae, which include the polyomaviruses and 
vacuolating viruses. Papillomaviruses derive their name from 
the Latin word 'papilla', meaning nipple or pustule, and the 
Greek suffix -oma, denoting tumor. This is a befitting 
etymology for a virus known to cause warts. The viral 
etiology of warts was first demonstrated in 1905, when Ciuffo 
demonstrated viral transmission using a cell-free filtrate 
(10). The first Papillomavirus was described by Richard E. 
Shope, when he identified the Cottontail Rabbit Papillomavirus 
as the etiologic agent in infectious Papillomatosis in rabbits 
(44) . 
Transmissible Papillomaviruses have now been described in 
over twenty species of animal, including cows, horses, deer, 
rabbits, dogs, birds, elephants, and primates, including man. 
Transmission frequently occurs between members of the same 
species, a principle which has had major economic 
ramifications for cattle raisers and for kennel owners who 
must vaccinate their dogs with a prophylactic vaccine prepared 
from a suspension of Canine Oral Papillomavirus. 
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Papillomaviruses from cattle, deer, sheep and Cottontail 
rabbits can induce tumors when experimentally transmitted to 
other species, but naturally occurring infectivity between 
species seems only a slight possibility (8) . A unique HPV, 
type 7, has been identified in the hand warts of butchers and 
veterinarians. Hybridization studies using probes made from 
BPV1 and HPV1, 2, 3, 4, and 5, were unable to detect the viral 
DNA, and restriction analysis showed it to be distinct from 
known HPVs and BPV1, 2, 3, and 4. Nonetheless, it is possible 
that this viral type represents an example of cross-species 
infectivity with an unrecognized bovine, porcine, or ovine 
type (45). 
Classification and Taxonomy 
The Human Papillomavirus, like all others of its type, 
is an icosahedral nonenveloped virus containing only DNA and 
proteins. Each virion contains a single DNA molecule which 
is double stranded and circular. The HPV genomes are all 
approximately 8000 base pairs in length, ranging from around 
7200 to 8000 base pairs. 
Study of the structure and behavior of the Human 
Papillomavirus was hampered for many years by the inability 
to culture infected cells in vitro. The virus infects 
epithelial surfaces, causing proliferations which are usually 
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benign, but which can lead to malignant growth. Replication 
of the virus apparently relies on factors present in 
differentiating keratinocytes; efforts to create a culture 
system capable of supporting such growth have not been 
successful as yet (8) . The development of recombinant DNA 
technology, with the creation of cloned plasmid containing 
HPV DNA, has enabled researchers to delve into the intricacies 
of this elusive virus. HPVs have been classified into types 
and subtypes based on liquid phase hybridization followed by 
SI nuclease digestion. If the viruses being compared show 
homology of less than 50% by this method, the unknown is 
considered a new type. A subtype is defined as an unknown 
which shows more than 50% but less than 100% homology with the 
prototype under these conditions. A reliance on known 
prototypes clearly limits the ability to identify new, 
distantly related viral types. It is important to understand 
that when the nucleotide sequences of different viral types 
are compared by heteroduplex analysis, far more than 50% 
homology may be found (10). The complete genomes of HPV types 
1, 5, 6, 8, 11, 16, 18, 31, 33, and 52 have been, or are in 
the process of being sequenced (9) . As more extensive 
sequence data for all the types emerges, a sequence based 
classification system may prove to be clinically useful. 
It has long been recognized that different HPV types have 
a predilection for infection of different parts of the body. 
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HPV-1 and HPV-2 typically cause plantar warts on the soles of 
the feet and hands respectively. Types 6 and 11 are most 
frequently found in benign exophytic genital warts, or 
condylomata, on the external genitalia and surrounding the 
anus. Type 16 and 18 have a preference for the epithelium of 
the uterine cervix, and HPV type 13 has only been described 
in the oral papillomas of Heck's disease. These observations 
have led to a clinical classification of the HPVs by a type- 
specific preference for different cell types and anatomic 
locations. The broadest categorization groups the types into 
those that infect cutaneous surfaces and those that infect 
mucous membranes. The preference of different types for 
different locations on the body has been suggested to be an 
evolutionary response to different types of keratinization 
within the body (4 6) . 
Pathogenesis 
Twenty-three of the 60 HPVs identified thus far have been 
found to infect the genital tract:6, 11, 16, 18, 33, 35, 30, 
34, 39, 40, 42-45, 51-59 (9). Of these, types 6,11,16, and 
18 are most frequently identified. The sexually transmitted 
nature of HPV infection was first described in 1954 by Barrett 
et al.(30). The authors reported on a cohort of 24 women, all 
of whom had first noticed the appearance of genital 
condylomata within 4-6 weeks of their respective husbands' 
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return from a military tour in the Far East. When questioned, 
all the men admitted to a sexual encounter in the Far East, 
and all had recently had penile warts. In 1990, HPV infection 
is acknowledged to be the most common sexually transmitted 
disease in the United States (84, 87). 
The virus is thought to enter the epithelium through any 
minor abrasions or breaks in the skin. Infection does not 
usually result when innoculums are introduced onto intact skin 
(31). The virus infects the basal cells, which rest against 
the basement membrane in the lowest strata of the epithelium. 
Apparently the virus requires a cell which is still capable 
of dividing to initiate infection (8) . The basal cells are 
nonpermissive for vegetative viral growth, and HPV DNA has 
been detected only in small quantities in the basal and 
parabasal cells (32, 33). Papillomavirus DNA is detected with 
increasing frequency in the differentiated cells above the 
basal layer (33). The virus probably replicates and is 
assembled in these keratinizing cells, with the infectious 
virions being shed in the desquamating squames. This model 
would help to explain why the cervical squamocolumnar 
junction, with its exposed junction of rapidly proliferating 
cells, would serve as a likely site of viral entry, and is the 
site at which around 90% of cervical carcinomas originate (8). 
This model also supports the notion that the presence of other 
sexually transmitted diseases which inflame or otherwise 
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compromise the integrity of the epithelium (herpes, syphilitic 
chancre, trichomonas etc.), may facilitate infection with 
viruses such as HPV. 
Latent infection may persist by episomal replication in 
the basal cells, without progression through the keratinizing 
process (10). HPV DNA has been detected in normal appearing 
epithelium both adjacent and distant to observed lesions (18, 
29, 59). It is not known how long the virus may remain in such 
a state or what might instigate a productive infection. 
Spontaneous regression of disease is freguently observed, 
although whether this a true regression or simply a reversion 
to latency is not clear. 
There are a number of morphologic features associated 
with HPV infection on histologic examination. The findings 
associated with productive viral replication are an appearance 
of hyperplastic proliferations of the basal and parabasal 
cells (acanthosis), a degenerative cytoplasmic vacuolization 
(koilocytosis), and variable thickening of the more 
superficial cell layers (hyperkeratosis and parakeratosis). 
Other findings include nuclear wrinkling, pyknosis, 
binucleation, and more severe forms of nuclear atypia 
including enlargement, irregular chromatin clumping, and 
hyperchromasia. 
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Prevalence 
The prevalence of genital tract infection with Human 
Papillomavirus is not known. Estimates vary according to the 
study design, the subjects and population, the type of 
specimen selected for analysis (ie. tissue or cytology 
specimen), and most significantly, the detection method used. 
Estimates of prevalence rates in the population with normal 
cytology range from 9% using filter in situ hybridization to 
80% using the recently developed polymerase chain reaction 
(18, 29). Any consideration of prevalence must take the above 
mentioned variables into account. 
Pregnancy 
A study examining the prevalence of HPV amongst pregnant 
women arrived at an rate of 28% (19). In this study cervical 
smears from 92 pregnant and 96 nonpregnant women were tested 
for the presence of HPV DNA by Southern blot hybridization and 
probes for HPV types 6,11,16 and 18. Pap smears taken 
simultaneously with the sample smear showed no evidence of CIN 
or HPV infection, and none of the women had a history of a 
previously abnormal Pap smear. The subjects were age matched 
and were all sexually active. 
HPV DNA was detected in 26(28%) of the pregnant subjects, 
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and in 12(12.5%) of the nonpregnant subjects, making the 
detection of HPV DNA 2.3 times more frequent in the pregnant 
population tested. HPV of type 16 was the type most frequently 
identified, accounting for 42.3% of the HPV positive smears 
amongst the pregnant women, but only 25% of the positive 
smears among the nonpregnant group. When estimates of the 
amount of viral DNA in a specimen were made, 85% of those from 
pregnant women contained more than 1.0 pg. of HPV DNA, while 
the majority of specimens from nonpregnant women (80%), 
contained less than 1.0 pg. In both groups of subjects the 
amount of viral DNA in HPV 16 positive specimens was higher 
than that found in specimens containing other types. The 
authors draw on these results to suggest that the state of 
pregnancy allows for the reactivation of HPV and increased 
viral replication. It must also be considered that an enhanced 
ability to sample the squamo-columnar junction during 
pregnancy due to columnar eversion might also contribute to 
the increased rate of and viral recovery detection. 
It is commonly observed that condyloma acuminata often 
flourish during pregnancy, only to regress in the post partum 
period (47). Both hormonal influences and an altered state of 
immunity have been proposed as contributing factors (22). 
Studies of immunosuppressed or immunodeficient populations 
also show a higher rate of HPV infection and associated 
neoplasia. Renal transplant patients on chronic 
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immunosuppressive therapy, and HIV positive patients form the 
patient populations for most of these investigations (48, 49) . 
Epidermodysplasia Verruciformis (EV) is a rare disease 
with an apparently autosomal recessive pattern of inheritance. 
It is characterized by an impaired cell mediated immunity, and 
by widespread skin lesions induced by HPV of specific types. 
Patients with EV have a high incidence of cutaneous cancers, 
usually in sun-exposed areas. This disease has served as a 
model in which to study the interaction between immunologic 
function and HPV infection (8) . 
Genomic Organization 
Most of the initial work on the genomic organization of 
the HPV was worked out using the BPV. The details that follow 
concern the BPV1 genome, but will be related to the HPV. All 
the Papillomaviruses have the same basic organization; early 
transcriptional units E1-E8, two late transcriptional units 
LI and L2, as well as a long noncoding region also known as 
the upstream regulatory region (URR). The open reading 
frames (ORFs) of the Papillomavirus are all located on the 
same DNA strand and show considerable overlap. Some function 
has been localized to each of the 8 ORFs, with the exception 
of E3. The E3, E5, and E8 ORFs are not as highly conserved as 
other portions of the genome and may not be present in all 
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Papillomaviruses. Over 90% of the genome is accounted for by 
coding regions. 
The transforming (early) segment of the BPV1 genome 
contains the eight ORFs, E1-E8. The El ORF is the largest of 
the eight and overlaps slightly with E2. It has the capacity 
to encode a polypeptide of 68 kilodaltons (K). This protein 
has been shown by mutational analysis to have a critical role 
in episomal replication; cells transformed by virus 
selectively mutated in the El ORF show Papillomavirus 
integration (50). The E2 ORF encodes a 45K polypeptide, and 
overlaps completely with E3, which lacks its own start codon, 
and must be spliced to an upstream exon if it is to be 
expressed as a functional polypeptide. The BPV E4 also 
overlaps with E2 and codes for a 12K polypeptide. Both the E2 
and E4 proteins appear to be involved in the transforming 
process. The E5 is found at the 38 end of the early region. 
It encodes a very hydrophobic polypeptide, a 44 amino acid 
membrane-associated transforming protein. The E8 ORF has a 
variable location in different Papillomaviruses and is 
probably not functional. The E3 and E5 ORF8s are not found in 
all the Papillomaviruses. 
The E6 and E7 ORFs are found at the 58 part of the 
transforming region where they overlap slightly. The two code 
for polypeptides of 16K and 14K respectively. These gene 
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products seem to be important in transformation; Harlow et al. 
showed that the HPV16 E7 gene product, a nuclear 
phosphoprotein, binds to the retinoblastoma protein, the 
product of a cellular antioncogene (13). In addition, the 
HPV16 E7 protein can cooperate with ras to transform baby rat 
kidney cells and transactivates the adenovirus E2 promoter 
(51) . 
The LI and L2 ORFs of the late region code for 
polypeptides with predicted weights of 55.5K and 50.IK 
respectively. Both these ORF's code for proteins present in 
the Papillomavirus capsid, although LI appears to code for the 
majority of the protein, VP1 (8). The noncoding or upstream 
regulatory region has several portions which are AT rich, and 
several nearly perfect palindromes. It is presumed to contain 
control elements for DNA replication and transcription (8). 
As mentioned earlier, the Human Papillomaviruses have an 
organization very similar to the Bovine Papillomaviruses. 
When compared to HPV1, the E8 ORF was not in a corresponding 
position, although the other ORFs were in equivalent 
locations. Portions of the El, E2, LI and L2, contained 
notable homologies. Within the E6 and E7 ORFs, although there 
was less homology, there were certain common characteristics. 
These common findings were also true of HPV6. For instance, 
the amino acid sequence Cys-X-X-Cys is repeated four times in 
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the predicted E6 polypeptide of both genomes (BPV1 and HPVla) . 
In the E7 ORF the same motif is repeated twice in both 
genomes. There are also similarities in the noncoding regions. 
Transforming Properties 
The HPV detected in malignant lesions is usually in an 
integrated form, while that detected in benign lesions is 
typically in an episomal state (10, 41). HPV 16 and 18, which 
together account for more than 90% of all the HPVs identified 
in cervical tumor specimens, are usually found to be 
integrated in higher grade lesions and carcinomas, while other 
lower grade lesions harbor HPV DNA in episomal form, with 
proportionately more infections with types 6 and 11 (8, 38, 
41, 88). Several immortal cell lines, Hela, SW756, C4-1, 
SiHa, and Caski contain integrated HPV DNA and are derived 
from cervical carcinomas. The first three contain HPV type 
18, and the latter two, DNA of type 16 (8). It appears that 
integration results in a deregulation of cellular controls, 
however, integration does not necessarily lead to 
transformation; several benign lesions have been shown to 
contain integrated HPV DNA, and rarely a cervical carcinoma 
will contain HPV DNA in episomal form (52) . It is possible 
that integration is not the transforming event, and rather, 
that transformed cells are somehow permissive of integration. 
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During integration the El, E2, and E5 as well as the late 
ORFs are disrupted. This may lead to deregulation of the E6 
and E7 ORFs, which remain intact during the integration event. 
The upstream regulatory region is also reliably conserved 
despite integration. Both the E6 and E7 ORFs undergo 
transcription and translation into viral proteins and appear 
to be required for the transforming properties (35, 53). As 
mentioned above, the E7 protein has recently been shown to 
bind a protein product of the Retinoblastoma gene, a model 
antioncogene. When inactivated, the RB protein is effectively 
eliminated from the cell, and increased cell proliferation and 
oncogenesis may be allowed (34). 
A recent paper discussed the differences between the E7 
protein of HPV type 16, associated with a high percentage of 
cervical carcinomas, and type 6b, a nononcogenic type (15). 
The E7 proteins differed in a number of ways. First, they had 
different electrophoretic mobilities in SDS-PAGE; type 6b 
resolved into three distinct species, the slowest of which was 
phosphorylated. Second, the HPV16 and 6b E7 proteins had 
different sedimentation properties in nondenaturing glycerol 
gradients. Third, and most significant, the E7 proteins of 
these two types had different capacities to bind the RB 
protein; the HPV6b product bound much less extensively than 
the type 16 product. Apparently binding only occurred with the 
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phosphorylated species of type 6b. These findings suggest that 
the oncogenic capacity of various types of HPV may be 
partially determined by the affinity of the E7 gene product 
for the RB protein. The authors postulate that cellular 
changes such as enhanced activity or higher levels of kinase 
in host cells containing HPV6b could lead to more effective 
binding of the RB protein, and more effective oncogenesis. 
This may account for the rare finding of type 6b in 
malignancies (34). 
Human Papillomavirus and the Association with Cervical Cancer 
The epidemiology of cervical cancer suggests an 
infectious, 
sexually transmitted agent. There are several pieces of 
evidence to support this model. First, cervical cancer is rare 
in nuns and sexually abstinent women (54, 55). Second, a 
positive association exists between the development of 
cervical cancer and early age at first coitus, multiple sexual 
partners, and the presence of other sexually transmitted 
diseases (56). Third, a woman whose husband has been 
previously married to a woman with cervical neoplasia, has 
herself a four-fold greater risk of developing cervical cancer 
(57) . Fourth, an increased incidence of cervical cancer has 
been documented in the wives of men with penile carcinoma 
(58) . Fifth, the incidence rates of cervical and penile 
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carcinoma are proportional, even across wide variations in 
incidence. 
Until recently the Herpes Simplex Virus 2 (HSV-2) was 
considered a likely etiologic agent for cervical cancer. This 
notion was based primarily on seroepidemiologic studies which 
consistently showed patients with cervical cancer to have 
higher HSV-2 antibody titers than matched controls, and also 
on the demonstrated oncogenic potential of partially 
inactivated HSV-2 in rodent cells. Using DNA-RNA 
hybridization techniques some workers have found HSV RNA in 
malignant and premalignant cervical tissues, but in only one 
case has HSV-2 DNA been detected in a cervical cancer specimen 
(86) . 
The demonstration of HPV DNA in the majority (90%) of 
cervical cancer specimens, as well as in 75- 95% of CIN 
lesions of all grades (CIN1-3), suggests that HPV may be a 
cofactor in the development of this disease (35, 38, 64). HPV 
DNA has also been detected in other genital tract tumors (17, 
39, 60). In a recent series of 53 Penile carcinomas, 27/53 
(51%) were found to contain integrated HPV DNA. 26 of the 27 
were type 16 and one specimen was type 18 (39). The authors 
suggested that this might be an underestimation of the actual 
presence of HPV; when two tissue samples from a known 16/18- 
positive specimen were analyzed, only 33% were positive in 
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both samples. Another study examined 16 vulvar carcinomas for 
the presence of HPV DNA (17). Fourteen of 16 (88%) contained 
HPV DNA, 13/16 (81%) type 18. HPV has also been detected in 
carcinomas of the vagina, and anus (60). The recent attention 
focussed on HPV as an oncogenic agent has led investigators 
to look for the virus in malignancies outside the genital 
tract (40) . 
HPV also exists in a multitude of benign lesions, most 
notably condyloma accuminatum. The DNA can also be found in 
normal epithelium in genital areas of patients with 
condylomata, and in the normal cervix (61, 59). There seems 
to be a range in oncogenic potential amongst the HPV types, 
with type 6 and 11 representing a more benign agent, and types 
16 and 18, seemingly more aggressive forms of the virus. A 
recent review of four studies demonstrated an inverse 
relations ship between the detection of types 6 and 11 and 
increasing grade of cervical intraepithelial neoplasia, and 
a positive association between types 16 and 18 and increasing 
grade (10, 64). Type 16 is the HPV most commonly found in 
cervical neoplasias and CIN lesions. It has been suggested 
that type 18 is found more frequently in adenocarcinoma of the 
cervix (62). Southern blot analysis of 11 primary 
adenocarcinomas detected HPV18 in 5 (45%) of the tumor 
specimens, and type 16 in 2 of 11 (18%) (36). It has been 
proposed that type 18 is associated with approximately 35% of 
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cases of a "rapidly progressive cervical cancer," defined as 
cervical cancer occurring within three years of the last true 
negative Pap smear. This type of tumor affects a population 
which is distinguished by younger age, higher socioeconomic 
class, more advanced disease at time of diagnosis, and greater 
reported frequency of benign gynecologic conditions (uterine 
leiomyomata, vaginitis) when compared to a control cervical 
cancer group (63). However, when Koutsky et al. conducted a 
review of ten studies of squamous cell carcinomas and seven 
studies of adenocarcinoma, HPV type 18 was detected in 32/281 
(11%) of the squamous carcinomas but only 6/31 (19%) of the 
adenocarcinomas (10) . This phenomenon clearly requires further 
investigation, and control for sampling error (see section on 
Pap smear collection). 
On the basis of broad epidemiologic studies of the 
association between different types of HPV and cervical 
lesions of all grades, types 16 and 18 can be considered "high 
risk" for carcinogenesis and types 6 and 11 can be considered 
"low risk." Types 31, 33, and 35 may be viewed as 
"intermediate-high risk" (64). Assignments of associated risk 
are valuable as general prognostic indicators, but it is 
important to realize that types 6 and 11 have been identified 
in some cervical cancers and types 16 and 18 do exist in 
normal epithelium without evidence of disease (64, 88) . Thus, 
infection with any of the types of HPV should be considered 
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to carry some risk of carcinogenesis. Coinfection with more 
than one viral type has been reported to occur in between 3 
and 20% of cases of infection (66) . It has been proposed that 
coinfection may result in a synergistically enhanced 
progression of dysplasia. It is also possible that 
recombination occurs between different viral types, resulting 
in a more oncogenic form. 
A patient at high risk for cervical neoplasia has been 
described in the literature (56-58). Early age at first 
coitus, early age at first pregnancy, multiple sexual 
partners, a partner with penile condylomata or penile cancer, 
and a history of an abnormal Pap smear can all be considered 
risk factors. A history of HPV infection, infection with other 
sexually transmitted diseases, and immunosuppression or 
deficiency have all been linked to the development of cervical 
disease. 
In addition, several cofactors have been suggested for the 
oncogenesis of HPV on the cervix. Among these are HIV, HSV, 
GC, Chlamydia, bacterial vaginoses, bacterial metabolites, and 
mutagenic degradation products. Cigarette smoking, vitamin 
deficiencies, and the use of oral contraceptives have also 
been proposed (10). 
The association between cervical cancer and early age at 
X 
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first intercourse, early age at first pregnancy, and the use 
of oral contraceptive agents may all be explained by the fact 
that the transformation zone (squamocolumnar junction) is most 
exposed during adolescence and in excess estrogenic states 
(ie. pregnancy and oral contraceptive use) , therefore creating 
an easy venue for viral entry. It is also possible that the 
increased prevalence in populations with these "risk factors" 
is a result not of increased rates of infection, but rather, 
of increased rates of detection due to columnar eversion and 
enhanced sampling, and is a truer estimate of prevalence. 
As discussed earlier, HPV DNA exists in episomal form in 
condyloma accuminatum and in all grades of CIN. When cervical 
carcinoma specimens are examined, the DNA is found to be 
present in an integrated form. The eight immortal cell lines 
described earlier also all contain HPV DNA in its integrated 
form. Integration is currently believed to be a critical and 
determinant step in malignant transformation by DNA animal 
viruses in vitro and in tumor production in vivo. The E6 and 
E7 ORFs are always maintained intact during integration, and 
code for proteins whose transforming properties are presently 
being investigated. The fact that HPV DNA exists in the 
integrated form in cancer specimens is strong evidence in 
support of a causal relationship. 
There are, of course, several possible explanations for 
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the close association between HPV and cervical cancer other 
than a direct causal relationship. It is possible that HPV 
is simply an eager opportunist of cell dysgenesis, or is made 
more easily detectible by dysplastic change. Perhaps 
integration is permitted only by a transformed cell, and the 
integrated HPV DNA represents a result rather than a cause of 
cell transformation. Despite these explanations, at present 
there is substantial evidence in support of a etiologic role 
for HPV in cervical carcinogenesis. 
The Pap Smear 
In 1928, George Papanicolaou and Aureli Babes, a Rumanian 
pathologist, independently introduced the notion of using 
exfoliated uterine cervix cells found in the vaginal pool as 
a means of detecting cervical cancer. Over the next two 
decades Papanicolaou furthered his studies of this cytologic 
phenomenon and in 1943 he published the monograph, Diagnosis 
of Uterine Cancer by Vaginal Smear. In 1947, J. Ernest Ayre, 
a Canadian gynecologist, determined that a sample of cervical 
cells obtained by direct sampling from the cervix with a 
wooden spatula produced a smear which was more efficient and 
simpler to examine (67). Hence the Pap smear and one of its' 
implements, the Ayre spatula, were born. 
The use of the Pap smear to sample cells from the uterine 
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cervix, with subsequent interpretation by a cytologist, has 
enabled physicians to detect occult cervical carcinomas and 
its precursor lesions. Because the prognosis for a patient 
with cervical cancer is determined by the clinical stage of 
disease at the time of diagnosis, the Pap smear has assumed 
a highly important role as a cancer screening test. In the 
United States, mortality from cervical cancer has decreased 
over 70% in the past 40 years (43). This dramatic improvement 
can be attributed in large measure to the use of the Pap 
smear, leading to detection of cancers at earlier stages of 
disease, and to the regular visits to the physician that 
accompany the use of this screening test. 
Despite striking improvements in early cancer detection, 
there are many flaws in the application of the Pap smear. The 
use of the pap smear has never been evaluated in a prospective 
fashion for obvious ethical considerations. Nor has the 
efficacy of different screening intervals been subjected to 
prospective analysis; different medical organizations have 
advised different schedules for routine screening. The use of 
a varied nomenclature for describing cervical cytopathology 
has contributed to confusion in the referring physician's 
interpretation and management of potentially precancerous 
lesions. Finally, false negative readings of abnormal pap 
smears and poor reproduceability of interpretation, even by 
a single reviewer, has plagued the test. 
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It is not unusual for a patient diagnosed with cervical 
cancer to have a recent history of normal Pap smears (3, 71, 
85). In one study of 264 women who were evaluated and treated 
for primary epithelial carcinoma of the cervix (64% had stage 
I disease) , 97 women (37%) had a history of a normal pap smear 
within three years of diagnosis; of these, 48 (18% of the 
total) had had the normal smear within the past year. Twenty- 
one of the patients presenting with primary epithelial 
carcinoma (8%) had never been screened, and the results of 
previous pap smears were not available for 81 (31%) of the 
women. Finally, 8 of the women had normal Pap smears at the 
time of histologic diagnosis of cancer (3). This study was 
designed to assess the impact of different Pap smear screening 
intervals on the prevention of advanced disease. Nonetheless, 
it highlights the potential weaknesses in a reliance on the 
Pap smear as a screening test. There are a number of reasons 
that the Pap smear is not an infallible screening test. Some 
of these relate to the very nature of cervical cancer itself, 
and others to the collection, interpretation, and reporting 
of results. 
Specimen Collection 
The reliability of cervical cytology specimens is largely 
dependent on the skill of the clinician collecting the 
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specimen, the area sampled, and the method of specimen 
collection used. The majority of cervical squamous carcinomas 
arise at the squamocolumnar junction, or transformation zone. 
A mechanism for preferential infection of this portion of the 
cervix by the human papillomavirus has been proposed (see 
earlier text). In adolescents this zone is well exposed on 
the vaginal portion of the cervix, but as a women ages this 
cell junction moves rostrally, into the cervical os. 
Consequently, an adequate sampling of this region becomes more 
difficult in older women. A number of studies have correlated 
the absence of endocervical cells with a lower rate of 
detection of malignancy (68). It is generally accepted, 
therefore, that a Pap smear that does not include endocervical 
columnar cells does not represent a sampling of the 
transformation zone, and is unsatisfactory.Using this 
criteria, as high as 30% of all gynecologic cytology specimens 
received by some laboratories would be considered inadequate 
(69). It is possible that the so-called "rapidly progressive 
carcinoma", is a result of a type specific predilection for 
endocervical cells. While the cellular tropism of this 
particular HPV type remains unestablished, if in fact the 
virus infects the columnar cells of the endocervix, it may be 
escaping early detection because of poor sampling as described 
above. 
A recent development which may greatly enhance specimen 
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collection is the use of the endocervical "cytobrush" in 
conjunction with the Ayre spatula. In one study of 5716 Pap 
smears which were obtained using an Ayre spatula and 
cytobrush, 98% were found to contain endocervical cells. This 
was compared to 24,496 slides which were obtained with spatula 
alone, only 84% of which included endocervical cells (69). 
Another study compared the use of cytobrush and spatula to 
specimen collection by spatula and cotton swab. When 510 
slides prepared in each manner were examined, 12% of those 
using the spatula and swab lacked endocervical cells, while 
only 1.7% of those utilizing the cytobrush lacked these cells 
(5). Potential drawbacks to the use of the cytobrush include 
the need to reorient cytopathologists to interpreting the 
slides which can contain whole sheets of endocervical cells, 
as well as revealing an increased number of minor cytologic 
atypias. The abrasive effect of the cytobrush in the 
endocervical canal can also produce more bleeding than the 
commonly used cotton swab, and the resultant blood can obscure 
cells on the Pap smear. Another means of sampling cervical and 
vaginal cells is cervical aspiration, and cervicovaginal 
lavage (26). 
Because the Pap smear consists of only a sampling of 
cells, it cannot be considered truly demonstrative of the 
histologic state of the cervix. Even when Pap smears have been 
properly collected, there may be precancerous lesions on the 
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cervix which are represented only by a few atypical cells. 
Different lesions shed cells in a different fashion, and may 
be over or under represented on the Pap smear. In invasive 
cancer, the outer surface of the lesion can become necrotic, 
yielding a Pap smear obscured by debris, and failing to show 
any obvious cellular abnormalities. It has been suggested 
that all patients in a high risk group (such as adolescents 
at a sexually transmitted diseases clinic) be given routine 
colposcopy at the time of Pap smear (anecdotal) . Lesions which 
might escape detection by Pap smear would be recognized, and 
could then be confirmed by biopsy specimen. However, 
colposcopy is a time consuming procedure, which must be 
performed by highly trained personnel—the implementation of 
routine colposcopic screening would make for an expensive and 
time consuming evaluation in clinical settings already 
overburdened by patient load. Patients undergoing colposcopy, 
while at a high risk for cervical disease, would also have a 
greater likelihood of more innocent genital tract infections 
which could present falsely positive findings on colposcopy, 
This would lead to biopsy, thus generating a lot of additional 
pathologic material requiring interpretation. Also of note, 
the colposcopic examination is far more uncomfortable for the 
patient than a simple speculum exam and Pap smear. Patient 
compliance is already an impediment to annual screening by Pap 
smear alone; if routine colposcopy was added to annual 
checkups, compliance could decrease further. 
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Filter hybridization for HPV DNA has also been suggested 
as a screening test for patients at high risk for cervical 
neoplasia. This possibility will be discussed extensively in 
the following section. 
Cytopathologic Interpretation 
The evaluation of Pap smears is a poorly standardized and 
regulated process, without extensive and effective quality 
control. Recent reports in the popular press (Wall Street 
Journal, November 1, 1987), focussed on the Pap smear 
"industry", where the number of Pap smears which could be 
evaluated by a cytotechnologist within a certain time frame 
was largely unregulated. The presumption is that this results 
in an increased risk of abnormal Pap smears being read as 
normal. There has been little study of the time dependency of 
an accurate Pap smear evaluation, but it is generally believed 
that a thorough screening of a single slide requires at least 
five minutes, and that the recognition of cytologic 
abnormalities would suffer were less time allotted. 
Before issuing a license for interstate commerce, the 
Centers for Disease Control requires that a laboratory observe 
a quality control measure whereby 10% of all Pap smears read 
as negative be rescreened. Given the low rate of abnormal 
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smears (approximately 10% of all smears taken), this method 
could fail to detect inadequate evaluation. There are other 
quality control efforts made by dedicated laboratories. A 
histopatholoqic correlation can be made when biopsies have 
been taken, and a review of a patient's previous pap smears 
is often undertaken when a current smear is evaluated as 
questionable or abnormal. The 10% rescreening measure remains 
the only regulated quality control measure. The 
implementation of other measures is at the discretion of a 
particular laboratory. Only a few states require proficiency 
examination by those reading cytology. In New York, a 
competency examination has been required of personnel reading 
Pap smears. An analysis of a fourteen year period demonstrated 
a significant improvement in the performance of the 
pathologists (70) . 
There are clearly many improvements which could be made 
in the evaluation process at an administrative and regulatory 
level. At the foundation of these problems rests the fact that 
even when performed by expert pathologists, the interpretation 
of a Pap smear is extremely difficult. As described above, a 
sample of cells may not reflect underlying disease, and at 
best, the interpretation of cellular changes is a subjective 
process. 
A false negative Pap smear is one read as normal despite 
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the presence of disease. As discussed, the failure to detect 
disease can be a consequence of tumor behavior, sample 
collection, or smear interpretation. A review of five studies 
using a comparison of two smears to assess false negativity, 
found rates to range between 0.0% and 29.7% (71-75). 
Sensitivity rates calculated from these same studies ranged 
between 77.1% and 100% These studies were based on 
populations from whom both an endo and ectocervical specimen 
had been collected, and in whom disease was diagnosed within 
three years of the "negative" smear. Smears defined as false 
negative were those which were found to represent sampling or 
interpretive errors when reevaluated following a subsequently 
abnormal pap smear. These results are confounded by the fact 
that different instruments were used in specimen collection, 
the fact that cervical lesions can regress, persist, or 
progress, and that some cervical lesions will continue to be 
undetected even by the second Pap smear. Nonetheless, these 
studies confirm the fallibility of the Pap smear as a cancer 
screening test. 
Several studies have addressed the issue of inter¬ 
observer variability in the interpretation of Pap smears. One 
study investigated 339 cases of tissue proven cervical 
malignancy (carcinoma in situ, invasive squamous carcinoma, 
endocervical adenocarcinoma, and lymphoid malignancy involving 
the cervix) (25). A total of 66 (20%) of patients had had a 
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Pap smear interpreted as normal within a year of diagnosis. 
These cytology slides were obtained and rescreened by two 
pathologists who had no previous knowledge of the present 
diagnosis; "true negative" slides were interspersed amongst 
the study slides as a measure of internal control. The 
reviewers assigned the slides to one of three false-negative 
categories; (1)Sampling error—no malignant or dysplastic 
cells seen on review, (2)Screening error—malignant or 
dysplastic cells present but not recognized by the cytologist, 
and (3)Interpretation error—dysplastic or malignant cells 
marked by the screening cytologist but not interpreted as 
significant by the overseeing cytopathologist. Overall, these 
Pap smears represented a 20% false negative rate for the 
detection of malignant disease. After rescreening, sampling 
error was thought to account for 62% of these cases, screening 
errors accounted for 16% and interpretation accounted for 22% 
of the false negatives. For the purposes of this discussion 
"screening" and "interpretation" errors can be considered 
together, as they represent a failure on the part of the 
personnel responsible for recognizing malignancies. When these 
errors are summed, interpretive errors account for 38% of the 
false negatives. It should be noted that slides which the 
reviewing pathologists considered "unsatisfactory" were 
attributed to interpretive error, rather than being included 
in the "sampling error" group. Slides considered 
unsatisfactory contained few cells, had drying artifacts, 
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obscuring inflammation or necrosis, or showed heavy clumps of 
cells; slides which did not contain endocervical cells were 
not considered unsatisfactory. 
Another study by Horn et al. concerned the reliability 
of the characterization of HPV infection on a Pap smear (23). 
Two pathologists well experienced with the cytologic 
manifestations of HPV infection were asked to read 87 slides, 
a proportion of which were known to contain evidence of HPV 
infection as described by Meisels criteria (24). Approximately 
25% of these slides were then reintroduced into the screening 
system in an attempt to assess intraobserver variability in 
interpretation. The pathologists classified the smears on the 
basis of (1) the presence of absence of HPV infection, and if 
HPV was thought to be present, (2) the degree of certainty 
with which the diagnosis of HPV was made. 
The two pathologists agreed on the presence of absence 
of HPV infection 74% of the time. The kappa statistic was used 
to control for agreement which could be expected by chance 
alone; the value 0.38 reflects only a fair degree of 
agreement, but far more than would be expected by chance 
alone. Intraobserver reliability was found to be 96% for one 
pathologist, and 79% for the other. 
It is very significant that in Horn's study. Twenty 
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percent of the slides were considered to be borderline or 
questionable diagnoses of HPV, ie. one pathologist classified 
the slide as lacking evidence of HPV, and the other considered 
some evidence of infection to be present. In their paper on 
the cytologic patterns of condylomatous lesions of the cervix 
and vagina, Meisels et al. lament the ambiguity of 
interpretation of cytologic findings associated with HPV 
infection, and express concern that these findings are often 
misinterpreted as CIN1 (24) . In light of the unreliability in 
detecting HPV, and difficulties in interpreting the findings 
when present, a more sensitive and reliable means of 
identifying HPV infection is needed. 
Two recent studies examined both inter and intra-observer 
variation in the interpretation of cervical intraepithelial 
neoplasia in histopathological specimens. Analysis was 
conducted using the Kappa statistic; both studies found 
overall poor interobserver agreement. One study found 
agreement between reading pathologists was best on immature 
squamous metaplasia and CIN3, and that there was only poor 
agreement on CIN1 and CIN2 (7) . Importantly, it was found that 
the ability to distinguish morphologic changes typically 
associated with HPV infection resulted in the poorest degree 
of agreement in the study; little more than what would be 
expected by chance. It was concluded that HPV may induce 
morphologic changes which may exaggerate the apparent severity 
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of dysplastic changes in cervical epithelium. Analysis of 
intraobserver variation also showed poor agreement, but this 
parameter was assessed with unusually difficult cases, and may 
reflect some selection bias. The second study found that 
agreement was best with regard to invasive lesions, mediocre 
in grade III lesions, and poor for lesions of grade I and II 
(42) . The results of this study also revealed that even 
experienced histopathologists had difficulty distinguishing 
reactive proliferations of the epithelium (including changes 
due to the human papillomavirus), from CIN1. 
The use of the term "atypia" is often used to describe Pap 
smears.In theory, this diagnosis is made when the epithelial 
cells show slight to moderate alterations in nuclear size and 
morphology. These changes can include a nucleus 1.5-2 x normal 
size, binucleation, (finely granular and evenly distributed 
chromatin, chromacenters) and an indistinct perinuclear halo 
in an orangeophilic cytoplasm. There has been a great deal of 
controversy surrounding the appropriate management of patients 
with such findings. Several studies have shown that there is 
a high rate of neoplasia in patients with such smears (77-80). 
In one study, 406 women with "atypical'1 pap smears were 
referred for repeat Pap smear and colposcopic evaluation 
within six 6 weeks to 3 months of the original Pap smear (1). 
Biopsies and endocervical curettage were performed if 
appropriate. In 18.7% of the patients, CIN was documented 
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histopathologically at this return visit. While these findings 
may partly reflect problems with sample collection and the 
ability of cervical lesions to progress in severity over time, 
they also reflect the ambiguity in the interpretation of 
cervical smears, and the danger inherent in a vague 
classification system. 
Diagnostic Reporting Systems 
Three methods of describing cervical cytology specimens 
are currently in use and a new system has recently been 
proposed (6). The Papanicolaou classification (class I-class 
V) system is based on the certainty with which a 
cytopathologist can describe a smear as containing malignant 
cells. It does not provide for description of non-cancerous 
findings. The World Health Organization developed a system for 
describing Pap smears along a continuum from "normal", to 
"invasive squamous carcinoma," with the premalignant lesions 
designated as mild, moderate, or severe dysplasia. Pap smears 
have also been reported as ranging from normal, through grades 
of cervical intraepithelial neoplasia (CIN1, 2, and 3) to 
invasive squamous cell carcinoma. Both of the latter two 
systems had the advantage of describing the findings in 
morphologic terms, but years of experience showed that there 
was a great deal of variability in the assignation of these 
terms, and poor reproduceability among readers. In an effort 
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to minimize the ambiguity of the terminology, and to reduce 
the confusion generated for clinicians using these reports for 
clinical management decisions, the participants of a National 
Cancer Institute Workshop held in December, 1988, proposed a 
new system for reporting Pap smears. This system, known as the 
Bethesda System, classifies all precancerous lesions as "Low 
grade Squamous Intraepithelial Lesion" (SIL), and "High Grade 
Squamous Intraepithelial Lesion." These terms encompass the 
descriptive terms which have been used previously. Low grade 
squamous Intraepithelial lesions are those showing cellular 
changes associated with HPV infection, and mild dysplasia 
(CIN1). High grade SIL encompasses morphologic changes 
previously described as moderate, and severe dysplasia, and 
carcinoma in situ. 
The Bethesda system limits the use of the term "atypia" 
to describe those findings which are of "undetermined 
significance." Specific mention was made in the report from 
the NCI workshop that the term not be attached to otherwise 
defined inflammatory, preneoplastic, or neoplastic cellular 
changes. The guidelines for cytologic description include all 
these categories. The workshop also recommended that a 
cytopathology report provide a statement on the adequacy of 
the specimen. 
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Detection Methods 
There are a number of means of detecting HPV infection 
of the genital tract. Some of these rely on morphology and 
are used clinically, and others use nucleic acid hybridization 
and other molecular biology techniques to recognize the 
presence of the virus. 
Gross Inspection 
Condyloma acuminata can usually be detected by gross 
inspection of the genitalia. An application of 3% acetic acid 
and the use of a magnifying hand lens will reveal more subtle 
lesions. Raised, condylomatous lesions are typically found in 
the region of the external genitalia, but are often in the 
mucous membranes of the anus, vulva, introitus, and vagina, 
and sometimes appear on the cervix. The fact that HPV DNA has 
been demonstrated in normal appearing epithelium clearly 
illustrates the limitations of gross examination. 
Colposcopy and Cerviography 
HPV-associated lesions on the cervix are often invisible 
to the naked eye, but can be seen with colposcopic examination 
after the application of acetic acid. Such lesions can be 
recognized by their white appearance, often with a slightly 

39 
raised, mosaic, or punctate pattern. 
Cerviography is a recently developed diagnostic method 
which combines the principles of colposcopy with a simple 
photograph of the cervix. The cervix is photographed after 
application of 5% acetic acid: abnormal cervical patterns can 
be recognized in the photographs by trained reviewers. A 
comparison of the Pap smear and cerviogram found the 
cerviogram to be significantly more sensitive, but less 
specific than the Pap smear for the detection of CIN lesions 
(76) . As with other means of detection, the inability to 
detect nonproductive (latent) lesions with these techniques 
limits their usefulness. In addition, both colposcopy and 
cerviography require highly trained personnel to carry out the 
examination and interpret the findings. 
Light Microscopic Examination of Cytologic and Histologic 
Specimens 
As has been discussed in some detail, pathologists 
examining cytology and tissue specimens using light 
microscopes have defined characteristic morphologic changes 
associated with HPV infection. The koilocyte is considered 
pathognomonic, but viral changes are often difficult to detect 
in the higher grade lesions of CIN, and there is substantial 
interobserver variation in the identification of viral 
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associated findings (23). 
Electron Microscopy 
The electron microscope has been used to examine 
specimens for the presence of HPV viral particles. Although 
particles of the appropriate size and structure have been 
identified in the cells of condyloma accuminatum, flat 
condylomas, and dysplasias, they have only been seen in 10- 
50% of the specimens thought to show evidence of HPV infection 
by clinical, cytologic, or histologic criteria. In addition 
to the apparently low sensitivity of this method, it is a time 
consuming process reguiring a skilled technician (81, 82). 
Immunohistochemistry 
Immunohistochemical techniques have been applied to 
testing for HPV. Anti-Papillomavirus antibodies have been 
raised in rabbits; the antiserum is commercially available and 
reacts with VP1, the major capsid protein encoded by the LI 
ORF of the Papillomavirus. Unfortunately, this technique is 
only able to detect capsid protein in approximately 50% of 
histologically positive specimens, and is limited to the 
detection of productive lesions. Because the LI gene product 
is expressed primarily in the koilocyte, the antigen becomes 
less detectible in the progressively higher grades of CIN as 
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koilocytes themselves are fewer in number. In addition, 
because commercially available antiserum is produced against 
BPV1 virions, different HPV types do not react equally well; 
for instance, BPV1 and HPV6 share more homology in the genus 
specific epitope of VP1 than BPV1 and HPV 16. "the genus 
specific epitope of the major capsid antigen is more closely 
conserved between BPV1 and HPV6 than between BPV1 and HPV16" 
(10). Thus, HPV16 is less detectible using this antisera. 
Antibodies to other viral proteins such as early region gene 
products will greatly enhance the sensitivity of this 
technique (10). 
Hybridization 
Nucleic acid hybridization has proven to be a far more 
sensitive means of detecting HPV DNA than any of the methods 
discussed thus far. A multitude of studies have documented the 
detection of HPV DNA in specimens with normal cytology using 
hybridization techniques (18, 19, 20, 25, 26, 27, 28). The use 
of these methods has added enormously to the understanding of 
the epidemiology and pathogenesis of HPV. 
Southern Blot Hybridization 
Southern blot hybridization is generally accepted as the 
most sensitive of the hybridization tests, and is considered 
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the "gold standard" for typing studies. Briefly, total 
cellular DNA is extracted from a specimen, and cut with a 
restriction enzyme known to have multiple restriction sites 
within the HPV genome. The resultant fragments are separated 
by electrophoresis on an agarose gel, denatured, neutralized, 
and transferred to a nitrocellulose or nylon filter according 
to a method described by Southern (83) . The filter is then 
hybridized with radiolabelled probes complementary to the DNA 
sequence being sought. Autoradiographic exposure will reveal 
a series of fragments of different lengths. 
Southern blotting is considered highly sensitive, capable 
of detecting as few as 0.1 copies of HPV DNA per cell when 
using 10 micrograms of cellular DNA as starting material (11). 
The procedure can be carried out with conditions of low and 
high stringency, and can thus be used to screen for the 
presence of HPV DNA and then used to test for more specific 
typing information. Human Papillomaviruses of different types 
will produce a characteristic pattern when cut with specific 
restriction enzymes. This has obvious applications for typing 
assays, but it also has the more general advantage of 
confirming that a positive result is in fact due to the virus 
in question, and not to nonspecific hybridization. The pattern 
of the restriction digest also permits differentiation between 
integrated and episomal forms of the virus, and allows for the 
identification of particular genomic fragments. 
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One of the disadvantages of this detection method is that 
it requires a relatively large amount of DNA. Such quantities 
of DNA can be recovered from a biopsy specimen, but less 
reliably from a cervical cytology specimen, thus necessitating 
more invasive sampling. The procedure is time consuming and 
labor intensive, and does not provide any information 
concerning the localization of HPV DNA within the specimen. 
Finally, the assay requires fresh tissue, and cannot be used 
for retrospective analysis. 
In Situ Hybridization 
In situ hybridization techniques probe tissue or a smear 
directly, without disrupting the normal tissue or cellular 
architecture. DNA or RNA probes can be generated, and can be 
made type-specific. The great advantage of this technique is 
that it provides information on the location and frequency of 
HPV infection within a specimen. This method enabled 
researchers to identify HPV sequences in normal and dysplastic 
tissue contiguous with cancerous regions of cervical tissue 
(84). It has also been possible to demonstrate the paucity of 
HPV sequences in the early basal and parabasal cells at the 
basement membrane, and the much higher copy number seen in 
more fully differentiated keratinocytes (33). Small samples 
are adequate for testing, and the technique can be applied to 
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paraffin embedded specimens, enabling retrospective study. 
In situ hybridization can also be used to detect mRNA, 
enabling the one to detect the expression of specific viral 
genes. 
Despite the advantages of in situ hybridization, its' 
principle limitation is that it is not as sensitive as other 
detection methods. In specific instances where only a few 
cells in a lesion harbor the HPV DNA, this method of detection 
may be more sensitive than techniques such as Southern 
blotting which essentially average the amount of HPV DNA 
present in a sample. In general, however, this method is not 
nearly as sensitive as other means, especially in frankly 
neoplastic specimens (19). 
Filter In Situ Hybridization 
Use of the filter in situ hybridization bypasses the time 
consuming DNA extraction process; cells collected by smears 
or cervical scrape are applied directly to a nylon membrane. 
After application, the cells are chemically disrupted, the DNA 
denatured, and the filter is probed with complementary 
radiolabelled or biotinylated nucleic acids. This is a very 
fast, simple means of detection which can be easily applied 
to large screening studies. Only a small amount of DNA is 
required. 
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This technique has a number of limitations. First, the 
results of this test provides no information on the 
localization of DNA sequences within the specimen. Like the 
Southern blot, it is essentially a DNA averaqinq assay. 
Second, non-specific siqnals from cellular debris may give 
false positive results (10). Third, a higher rate of dual 
infection has been reported using this technique; high levels 
of HPV of one type may result in cross reaction with another 
type-specific probe (10). Last, while superior to the in situ 
method, the sensitivity of this detection method is less than 
that of the Southern blot(19). 
Slot Blotting 
The slot, or dot blot method can be considered a hybrid 
of the Southern blot and filter in situ methods. First total 
DNA is extracted from the specimens. The DNA is denatured, 
neutralized and applied to a nitrocellulose or nylon filter 
using a slot or dot blot manifold. This apparatus effectively 
concentrates the applied DNA into a defined area. Labelled 
probes can then be hybridized to the filter. The slot blot 
method has a sensitivity comparable to the Southern blot when 
RNA probes are used (85). It is estimated that 1 virus/10 host 
cells could be detected by this method (20) . Only a small 
amount of DNA is required for this assay;this quantity is 
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easily provided by a cervical cytology specimen. The 
technique is readily applicable to large screening studies. 
Because of the possibility of false positives and 
nonspecific hybridization, this test must be carried out under 
highly stringent conditions. As with the filter in situ 
technique, specimens with large quantities of HPV DNA of one 
type may cross react with probes directed against a second 
type. Like the other techniques making use of DNA extraction, 
slot blot technique does not yield any information about the 
distribution or localization of HPV DNA in the specimen. 
The ViraPap Detection Kit 
The ViraPap Human Papillomavirus Detection Kit represents 
the first hybridization technique to be developed into an FDA 
approved detection kit for HPV. The method used in this study 
is essentially a modification of the filter in situ 
hybridization technique. Samples are collected from the 
endocervix using a dacron tipped swab and the exfoliated cells 
are stored in a transport media. The cells are chemically 
disrupted and the DNA denatured, and the solution is applied 
to a nylon membrane using vacuum filtration through a dot blot 
manifold. 32P labelled HPV RNA probes prepared by 
transcription from recombinant plasmid are then incubated 
with the membrane and hybridization occurs between the 
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membrane-bound sample DNA and the complementary RNA probes. 
The kit provides two positive controls which are dilutions of 
cells from the Hela cell line known to contain integrated 
HPV18 DNA, and a negative control of HTB-31 cells which 
contain no HPV DNA. 
The ViraPap test has been evaluated in comparison to 
Southern blotting technique by the manufactures. In a 
collaborative study conducted by four laboratories, cervical 
cytology specimens from 830 patients were tested for the 
presence of HPV DNA using the ViraPap and Southern blot 
technique. The ViraPap was shown to have a sensitivity of 
94.5% and a specificity of 95.5% when compared to Southern 
blot analysis (89). Intra and inter-laboratory 
reproduceability using a control panel prepared from the Hela 
cell line were 98.4% and 98% respectively. 
The ViraPap kit uses probes complementary to the DNA of HPV 
types 6,11,16,18,31,33, and 35. The advantage of using RNA 
rather than DNA probes lies in the greater stability of the 
RNA-DNA complex (when compared to a DNA-DNA complex), thus al¬ 
lowing the use of more stringent conditions. However, since 
the kit uses high stringency conditions, only these specific 
types will result in a positive test result. 
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Comparison of Different Hybridization Techniques 
It is important to understand that not only do these 
various hybridization tests have different sensitivities in 
the detection of histologically or cytologically documented 
disease, they also differ tremendously in their ability of 
detect HPV DNA in normal specimens with no evidence of 
disease. In addition, a given test method may have different 
sensitivities when applied to lesions of different grades. 
A study by Caussy et al. compared Southern blotting, 
filter in situ hybridization, and in situ hybridization for 
their sensitivity and specificity in the detection of HPV DNA 
in condylomas, cancers, and normal cervical specimens (19). 
Sampling of the normal and cancerous cervices was not 
colposcopically directed, but was obtained from gross 
hysterectomy specimens. The diagnoses of condyloma and 
cervical cancer were confirmed histologically, as was the 
absence of lesions in the group of normal cervical specimens. 
It is of note that of the 33 normal cervical specimens 9 were 
found to have cervicitis, and 11 had metaplasia. The remaining 
13 specimens were unremarkable. There was no evidence of CIN 
or HPV infection in any of these 33 specimens. 
Probes capable of detecting HPV DNA of types 6,11,16,and 
18 were used in this study. When the condylomas were assayed 
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by the three hybridization techniques described above, HPV DNA 
was detected in 82% by Southern blot, 62% by filter in situ, 
and 72% by in situ testing. When cancerous specimens were 
tested, HPV DNA was detected in 70%, 89%, and 30% of samples 
by Southern blot, filter in situ, and in situ hybridization 
respectively. Specimens which showed no histologic evidence 
of neoplasia or condylomatous changes were 13% HPV DNA- 
positive by Southern blot, 9.5% positive by filter in situ, 
and 6% positive by in situ. Condylomas and cancerous lesions 
were considered together for the purposes of calculating the 
sensitivities and specificities of disease detection. The 
Southern blot method had a sensitivity of 76%, and a 
specificity of 87%. The filter in situ technique had a 
sensitivity of 72% and a specificity of 90%, and the in situ 
technique, a sensitivity of 50% and a specificity of 93%. The 
sensitivity of the in situ method varied significantly between 
disease categories, with a sensitivity of 72% for condylomas, 
and only 30% for invasive cancer specimens. 
Finally, the filter in situ and in situ techniques were 
compared to the Southern blot method as a standard. This 
comparison yielded sensitivities of 66 and 61% and 
specificities of 88 and 86% for the filter in situ and in situ 
hybridization techniques respectively. 
The authors carried out experiments to determine the 
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lower limits of detection for each method. They concluded 
that the Southern method was capable of detecting 0.2 pg. of 
HPV DNA (0.2-0.3 copies per cell). The filter in situ method 
was capable od detecting as little as 0.1 pg. of HPV DNA. It 
was difficult to establish a lower limit in the in situ 
method, although, the authors were unable to detect Siha cells 
which contain 10 copies of HPV DNA per cell. They were able 
to detect Caski cells, which contain 500 copies per cell. 
Clearly, any attempts at establishing the prevalence of 
HPV infection in the general population (with and without 
evidence of disease), will be greatly confounded by the 
variability in testing technigues. Conservative estimates of 
the prevalence of HPV infection in the sexually active 
population between the ages of 15 and 49, propose a figure of 
10% (11). In a large population based study of cervical smears 
collected from 9,295 women attending gynecology clinics for 
routine screening, 8,755 (94.2%) of the smears were 
cytologically normal. 196 (2.1%) of the smears showed 
koilocytosis; 162 (1.7%) CIN1/2, 120(1.3%) CIN3, and 62 (0.7%) 
invasive cervical cancer. This study employed the filter in 
situ method to detect HPV DNA of types 6,11,16 and 18 in 
samples of exfoliated cells obtained at the same time as the 
cervical smear. HPV was detected in 9% of the cytologically 
normal smears; when CIN and invasive carcinoma were considered 
together, 40% contained HPV DNA (18). Only 30% of those 
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initially HPV—positive were detected by a follow up test 3 
months later, and a number of patients whose specimens were 
initially negative were found to have HPV DNA on follow up. 
In view of this finding, and the 40% detection rate amongst 
invasive cancers using the filter in situ method, the authors 
propose that the prevalence rate is likely to be 2-3 fold 
greater than that detected by their study. 
The Polymerase Chain Reaction 
The polymerase chain reaction is a recently developed 
method of nucleic acid amplification which permits the 
detection of extremely small quantities of target DNA. Since 
its description in 1985, this method has been applied to a 
wide range of pathogens ranging from chlamydia to HIV. 
The polymerase chain reaction requires a knowledge of the 
nucleotide sequence being amplified. A region of particular 
interest within a genome is selected for amplification. In 
the case of HPV this would most likely be a region which is 
highly conserved between different types, as this would give 
the widest range of detection. Once the target nucleotide 
sequence has been selected, stretches of nucleotides are 
identified, 25 to 30 base pairs long, and flanking the target 
region at the 5' and 3' ends. These flanking oligonucleotides 
are known as amplification primers and may be synthesized 
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using an automated DNA synthesizer. 
A sample presumed to contain the target DNA is mixed with 
the amplification primers, free nucleotides (A,T,G, and C) , 
and a thermostable DNA polymerase (such as TaqI). The mixture 
is subjected to a series of thermal cyclings. During each 
cycle the target DNA is denatured, the amplification primers 
anneal to their complementary sites, and the DNA polymerase 
extends the strand toward the other primers. After roughly 
30 cycles the target DNA concentration has increased 
exponentially, over 1 million fold. This so-called "PCR 
product" consists of approximately 1 microgram of DNA, and can 
be analyzed by dot blot or Southern blot techniques, or even 
run on a gel and stained with ethidium bromide. 
Theoretically primers can be designed which are type- 
specific, although this may be difficult within highly 
conserved regions. More typing information can be attained 
by a restriction enzyme digestion or by transferring the PCR 
product to nitrocellulose paper and hybridizing with type- 
specific probes. It has not yet been determined how many 
primer sets can be used simultaneously. 
There are a number of advantages to the use of this 
amplification technique. It is highly sensitive, minute 
quantities of DNA can be used as starting material, and the 
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reaction can be carried out on paraffin-embedded specimens 
without DNA extraction. This provides a good means of 
retrospective analysis. The procedure is relatively easy to 
perform, (although preparation can be labor intensive), and 
lends itself to possible automation. 
One disadvantage of the PCR is that it necessitates a 
knowledge of the genome being investigated. Whether new virus 
types or subtypes will be identified by this method remains 
to be seen. The clinical significance of the presence of 
viral DNA at a level only detectible following PCR has not 
been established. Finally, contamination of specimens or 
reagents with PCR amplification fragments can result in false 
positive results. Given the high sensitivity of this 
procedure, a single target fragment contaminating an otherwise 
negative specimen could easily produce a discernable 
amplification product. Contamination could also occur between 
specimens before processing, with a similar consequence. As 
a result of these contamination risks it has become crucial 
to run a large number of negative controls with each specimen 
being tested, and to take great care to avoid the dispersion 
of fragments in the laboratory by containment under a hood or 
use of a separate room. 
A number of studies have investigated the presence of HPV 
in clinical specimens using this reaction. Of particular 
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interest are recent estimates of HPV prevalence based on 
detection following the PCR. A study by Tidy et al. used the 
polymerase chain reaction to look for HPV16 infection women 
with normal cytology, "dyskaryotic" smears, or invasive 
cervical carcinoma (29) . The authors designed two sets of 
primers, A and B, which flanked a region in the upstream 
regulatory region, and C and D which recognized a segment 
within the E6E7 open reading frames. Each experiment included 
three controls, a positive control consisting of a known 
HPV16-positive cervical carcinoma, a negative control of DNA 
from the human cell lymphoblastoid line BJAB (HPV-negative), 
and water (to check for contamination). One hundred and forty 
normal cervical samples were tested with primers A and B; 84% 
of these specimens contained HPV DNA. Sixty-seven percent of 
the "dyskaryotic" smears contained HPV DNA, and 100% of the 
carcinomas yielded a positive amplification product. Twenty 
patients who had undergone laser treatment for CIN in the past 
and who were without evidence of disease at follow-up all 
showed a positive amplification product with the primers for 
HPV16. Primers C and D were used to confirm the findings in 
22 samples. All the samples considered negative with primers 
A and B were also negative with the second primer set. Five 
of the 18 specimens positive with primers A and B were 
negative on testing with C and D. The authors attributed the 
failure to detect HPV DNA in these five specimens to the lower 
sensitivity of a longer amplification product. The 
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amplification product produced with each set of primers was 
of the appropriate size as determined by gel electrophoresis, 
and gave the appropriate pattern when cut with a restriction 
enzyme. 
This study proposes a prevalence rate of HPV infection 
in the cytologically normal population far greater than that 
predicted using other detection methods. In addition it 
reports a greater rate of detection of HPV16 DNA in cervical 
carcinomas than has previously been described. Given the 
limitations of the PCR method discussed above, a study such 
as this one should be interpreted with caution. The primer 
sets used in this study flanked stretches within highly 
conserved regions of the HPV genome. Since there were no 
controls using samples containing HPV of different types, 
there is no assurance that these primers aren't amplifying a 
variety of different types of HPV, not simply type 16. Even 
so, the detection of HPV DNA of any type in such a large 
number of specimens from patients with normal cytology is an 
unprecedented finding. It is possible that HPV DNA does in 
fact exist in such a large percentage of the "normal" 
population, and has gone undetected because of the lower 
sensitivity of previously applied techniques. If HPV DNA is 
present in such a large proportion of the population should 
the understanding of the association between HPV and cervical 
cancer be revised? The clinical significance of detection of 
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HPV DNA by PCR is not at all clear. How much DNA should 
constitute an infection; is HPV a normal flora in some sense? 
It is also possible that the high rate of detection in this 
study reflects specimen contamination. Confirmation with a 
second primer set cannot allay fears that contamination 
occurred between specimens prior to PCR. The five specimens 
which were PCR positive by primers A and B only, may 
illustrate contamination with specific PCR fragments 
(fragments from the amplification with A and B, but not C and 
D) . 
A recent study analyzing the 210 smears which had served 
as the basis for the study described above found that the 
majority (63%) of women with normal smears were infected with 
type 16b, a previously unidentified subtype (15). This 
discovery was based on a slight difference in the molecular 
weight of the amplification products observed amongst the 
specimens following PCR. When the authors sequenced each of 
these products a new subtype was identified, differing from 
type 16 by a 21 bp deletion and 3 point mutations within the 
URR target being used for amplification. The authors found 
that less than 1% of the women with normal smears were 
infected with type 16a, and that dual infection with both 16a 
and 16b occurred in 20% of the normal specimens. Amongst the 
dyskaryotic smears, 43% had type 16a only, 20% were infected 
with type 16b only, and 7% showed dual infection. One hundred 
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percent of the carcinomas (22) contained type 16a alone. 
The authors propose that the deletion in type 16b. leads 
to the loss of the consensus E2 binding site with subsequent 
reduction in the transcription of E6 and E7, and altered 
oncogenicity. 
Both these studies serve to demonstrate the need for 
caution in interpreting the results of any new detection 
technique. Nonetheless, the PCR may allow for new methods of 
detection and may enlarge our understanding of disease 
transmission. An example of one such study is that done by 
Melchers et al., in which urine specimens were obtained from 
17 male patients known to have condyloma acuminata in the 
meatus urethrae (21). Urine was also collected from 14 male 
volunteers with no evidence of HPV related disease. After the 
urine was centrifuged, a DNA extraction was performed on the 
sediment, and was found to contain between 100 and 500 ng. of 
chromosomal DNA by agarose gel electrophoresis. The 
polymerase chain reaction was carried out with primers 
flanking portions of the type 6 and type 11 genomes, and 
subsequently analyzed with agarose gel electrophoresis and 
Southern blot hybridization. HPV DNA of types 6 and/or 11 
could be detected in 88% of the patients with condylomata 
acuminatum, but in none of the specimens from the control 
group. The authors conclude that urine specimens might provide 
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a means of screening for HPV infection, although such a method 
may only detect those men with infection in the urinary tract, 
and may miss those individuals with lesions of the squamous 
epithelium of the penis. The finding of HPV DNA in specimens 
presumably containing cells exfoliated from the genito-urinary 
tract also supports the notion that HPV could be transmitted 
to women in the semen of infected males. 
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MATERIALS AND METHODS 
Subjects 
The participants in this study were forty 
women who were referred to the Yale Gynecologic Oncology 
Clinic for evaluation of an abnormal Pap smear. The women 
ranged in age from 18 to 64 with an mean age of 30. Seven of 
the 40 women were pregnant at the time the study specimen was 
collected. 
The cytologic abnormalities that prompted referral to the 
Yale Oncology Clinic ranged in severity from "some features 
suggestive of condylomatous changes," to "carcinoma in situ." 
In most cases the study specimen was obtained at the time of 
the subject's initial evaluation at Yale; in a few instances 
the subject was already being followed at the Oncology Clinic, 
and the sample was collected during a return visit. Both 
initial and follow-up evaluation at the Oncology Clinic 
consisted of a pertinent history, and physical examination 
including a Pap smear, colposcopy, and endocervical curettage 
and colposcopically directed cervical biopsies whenever 
appropriate. The investigational use of the diagnostic test 
was explained to each subject, and with her consent an 
endocervical cytology specimen was obtained. 
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Specimen Collection 
Specimens were collected by Obstetrician-Gynecologists at 
the Yale Gynecologic Oncology Clinic using the ViraPap 
Specimen Collection kit. After visualization of the cervix 
and collection of a Pap smear using a cotton tipped swab and 
Ayre spatula, a dacron tipped swab was used to sample 
exfoliated cells from the endocervical canal. Immediately 
after sampling the swab was placed in 1 milliliter (ml.) of 
transport medium containing a cheiotropic agent and 0.05% w/v 
Sodium Azide to retard bacterial growth. Specimens were 
stored at room temperature for no more than one week before 
being frozen at -20 degrees Celsius for up to two months. 
In most cases colposcopy was performed immediately after 
ViraPap specimen collection. Any colposcopic findings (aceto- 
white change, abnormal vascularity, punctation, mosaicism, 
visible condylomata) were noted, and colposcopically directed 
cervical biopsies and endocervical curettage were carried out 
when appropriate. Cervical biopsies and endocervical 
curettage specimens were transported to the Department of 
Pathology in a 10% Formalin solution, prepared for light 
microscopy with Hematoxylin and Eosin staining, and read by 
pathologists in the Yale department of Pathology. Pap smears 
were screened by certified cytotechnologists and those with 
abnormal findings were referred to department pathologists for 
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interpretation. 
After approximately fifty specimens were collected, 
frozen samples were thawed and assayed. A technical service 
representative from Life Technologies supervised the 
processing of the specimens. In instances where the clinician 
had substituted a wood-shafted swab for the plastic-shafted 
swab provided in the manufactured collection kit, the specimen 
was discarded because of the possibility of a false negative 
result after wooden material has been stored in the transport 
media. Specimens which were not accompanied by a concurrently 
taken Pap smear were also disqualified from the study. In 
all, 40 specimens were deemed acceptable. Each specimen was 
numbered, and the date of collection, clinician attending the 
patient, as well as the subject's name, unit number and date 
of birth were recorded on a tally sheet. Special note was 
taken of the specimen appearance, and yellow, dark yellow or 
visibly bloody specimens were identified. 
ViraPap: HPV DNA Detection by Hybridization Techniques 
Specimens were prepared for hybridization according to 
the instructions provided in the ViraPap Human Papillomavirus 
DNA Detection Kit, and utilizing reagents provided in the same 
self-contained kit. The kit contains positive controls made 
up of disrupted Hela cells in ViraPap transport medium. Hela 
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cells are a transformed human cell line derived from a 
cervical carcinoma containing integrated copies of the HPV- 
18 genome. The high positive control contains 2.0 ml. of 1.0 
x 105 cells/ml., and the low positive control a higher 
dilution at 1.0 x 104 cells/ml. A negative control consists of 
1.0 ml of 5 x 105 cells/ml. disrupted HTB-31 cells, a 
transformed human cell line derived from a cervical carcinoma 
which does not contain any HPV sequences. All three controls 
were processed in the same manner as the patient specimens. 
Two drops of blue "Sample Preparation Reagent" were added 
to each specimen tube. This reagent is a bacterial protease 
which serves primarily to disrupt the integrity of the 
endocervical cells in solution and release the DNA into the 
medium. Each tube was recapped and vortexed and then 
incubated at 37 degrees Celsius for 1 hour. The samples were 
vortexed again following incubation and the dacron swabs 
removed after care was taken to express as much of the medium 
as possible. Two hundred and fifty microliters (ul.) of the 
sample was removed and placed in a 12 x 75 millimeter (mm) 
test tube and 750 ul. of "Sample Diluent," a dilute base 
solution, was added and the specimens were incubated at room 
temperature for five minutes. This basic solution effectively 
denatures any DNA present. Each 1.0 ml specimen was then 
placed in a well in the ViraPap Filter Manifold, and filtered 
through a presoaked nylon membrane with a vacuum pressure of 
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13mm Hg. 
The nylon membrane was then incubated at 60 degrees 
Celsius with a prehybridization reagent containing formamide, 
blocking reagents, stabilizers, and a kinetic enhancer. After 
a 30 minute incubation the membrane was blotted dry and the 
"Hybridization Reagent" was added. The hybridization reagent 
■ • • 32 
contains 5 microcurie of P labelled RNA probes complementary 
to the DNA of HPV types 6, 11, 16, 18, 31, 33, and 35. The 
membrane was then allowed to incubate at 60 degrees for two 
hours. 
When the hybridization incubation was complete the 
membrane was washed with two high stringency buffers and 
treated with an RNAse reagent to reduce nonspecific binding 
of the RNA probes. Wash #1 was a 0.26 M phosphate buffered 
saline solution containing 0.026 M EDTA and 4.8 M NaCl. The 
membrane was covered with 50 ml. of buffer and incubated at 
room temperature with gentle agitation for three minutes. 
These washes were carried out a total of three times. RNase 
reagent was then added to cover the membrane and allowed to 
incubate with shaking for 15 minutes at 37 degrees Celsius. 
One hundred and fifty ml. of Wash #2, a 100 mM phosphate 
buffered saline solution with 10 mM EDTA and 1% w/v SDS, was 
added and the membrane was incubated with shaking for 5 
minutes at 60 degrees. This wash was also carried out a total 
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of three times. When the washing procedure was completed the 
membrane was blotted dry and placed in a film cassette 
adjacent to Kodak type 57 film with intensifying screens, and 
allowed to expose at -70 degrees. The film was developed 
after 7 days (Figure 1). 
ViraType: Identification of three distinct viral groups 
The protocol accompanying the ViraType Human 
Papillomavirus DNA Typing Kit was followed during the typing 
procedure. Three type specific controls were provided in this 
kit. The controls were prepared from HPV DNA added to 
inactivated HTB-31 cells in transport media. One positive 
typing control contained HPV DNA of type 6 and 11, the second, 
HPV DNA of types 16 and 18, and a third, HPV DNA of types 31, 
33, and 35. A negative control contained only inactivated 
HTB-31 cells in transport media. 
Only those specimens which had yielded a positive ViraPap 
test were passed through the typing procedure, with the 
exception of two specimens which served as internal negative 
controls (Specimens #8 and #22). There were approximately 750 
ul. of the original specimen remaining after the protease 
treatment step carried out in the ViraPap protocol. Four 
hundred and fifty ul. of this specimen was transferred to a 
clean 12x 75 mm test tube. Two milliliters of Sample Diluent 
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(a chemical denaturing reagent) was added to each specimen, 
mixed thoroughly and allowed to incubate at room temperature 
for 15 minutes. Three separate nylon membranes were prepared 
for filtration and labelled 6/11, 16/18, and 31/33/35 
respectively. Each membrane was subsequently placed in the 
ViraPap Filtration Manifold and 800 ul. aliquots of each 
specimen were placed in corresponding wells on each membrane. 
The three positive controls and the negative control were 
applied to each of the three filters as well. After an 
aliquot of each sample had been loaded in the filter manifold, 
vacuum pressure was applied to 13 mm Hg. The manifold was 
washed well with soap and water after each filtering. 
Prehybridization was carried out using a formamide 
solution containing blocking agents and a kinetic enhancer. 
The three filters were incubated at 60 degrees for 30 minutes, 
and then blotted dry. There were three separate hybridization 
mixtures, each containing viral group-specific probes. The 
RNA probes in the ViraType kit were prepared by in vitro 
transcription of recombinant plasmid which each contain 
. . • • 32 
essentially the entire genome of a particular viral type. P 
labelled RNA sequences complementary to types 6 and 11 were 
added to one hybridization reagent, RNA complementary to types 
16 and 18 were added to a second, and RNA complementary to 
types 31, 33, and 35 to a third hybridization mixture. A 
separate membrane was incubated with each of the 
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hybridization reagents for two hours at 60 degrees Celsius. 
After the hybridization incubation the membranes were washed 
with the same high stringency washes used in the ViraPap kit, 
and likewise treated with an RNase reagent to minimize 
nonspecific probe binding. The schedule and seguence of steps 
were identical to those used in the ViraPap protocol. The 
membranes were then placed in a film cassette with Kodak type 
57 film and intensifying screens and exposed at -70 degrees 
Celsius. The film was developed after 7 days (Figure 2). 
Chart Review 
A chart review was made of all the gynecologic oncology 
records of participating subjects. The objectives were to 
ascertain gravity and parity, and most importantly, to 
document the colposcopic findings at the time of specimen 
collection and to review the final pathology reports 
concerning any concurrently taken cytology and pathology 
specimens. 
Pap smears taken at the time of ViraPap specimen 
collection were scored as positive (indicative of disease) if 
the cytologic interpretation included "atypia," "viral 
atypia," koilocytosis, "condylomatous changes," or any grade 
of CIN. Cervical biopsy and endocervical curettage specimens 
were scored similarly. In instances where the pathologist read 
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the cytology or histology as representing a range of pathology 
(ie. CIN1-CIN2), the more severe grade was recorded. Likewise, 
when multiple biopsies taken from a single patient yielded 
varying degrees of pathology, the most severe grade was 
recorded. Smears and biopsies showing "inflammatory atypia" 
were not scored as positive (see Appendix). 
Polymerase Chain Reaction 
Using the Wisc-5 computer program (Version 5, Sequence 
Management Software), the entire genomes of type 16 and 18 
were aligned and staggered so as to provide for the greatest 
degree of homology. The regions containing the E6 and E7 open 
reading frames (ORF's) were outlined on each genome and an 
effort was made to select stretches of nucleotides within each 
of the type 16 open reading frames that had little if any 
homology to the corresponding regions of type 18. Four 
oligonucleotides were chosen, each between 23 and 25 base 
pairs in length, and subsequently named HPV16-1, HPV16-2, 
HPV16-3, and HPV16-4. HPV16-1 and 2 lay within the type 16 
E6 ORF, and framed a sequence of nucleotides 183 base pairs 
long (including the length of the primers themselves). HPV16- 
3 and 4 lay within the type 16 E7 ORF and flanked a sequence 
163 base pairs long. The oligonucleotide primers were 
synthesized on a DNA synthesizer with Trityl on, and purified 
by oligopurification cartridge (Figure 3a). 
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The annealing temperatures of the primers were 
approximated based on the G, T, A, and C content of each 
oligonucleotide, and the PCR machine was programmed to cycle 
with an annealing temperature of 55 degrees Celsius. These 
conditions were thought to be stringent enough to minimize 
nonspecific binding, while still allowing for effective 
elongation. The Polymerase chain reaction was carried out 
using a protocol modified from the original Elmer Cetus form. 
A "master mix" was prepared containing all the components 
necessary for a DNA synthesis reaction except the DNA template 
itself: free nucleotides (Promega), Taq polymerase (a 
thermostable DNA polymerase, manufactured by Perkin Elmer 
Cetus), oligonucleotide primers flanking the region to be 
amplified (manufactured as described above), a detergent 
(Tween), lOx Buffer with a magnesium concentration of 15 mM, 
and water. In order to test the viability of the HPV primers 
before applying them to patient specimens, the polymerase 
chain reaction was first run with serial dilutions of pBR322 
plasmid containing HPV-16, kindly provided by Dan DiMaio's 
laboratory. A 1:10 serial dilution series was made of 
pBR322/HPV-16 plasmid (1.065 micrograms/ microliter) ranging 
o o 
from 1.0 x 10 to 1.0 x 10 . 5 microl. of each plasmid 
dilution and 45 ul. of "per master mix" were added to a 1.5 
ml. sterile siliconized Eppendorf tube. A drop of mineral oil 
was placed on top of each reaction mixture to minimize 
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evaporation during the thermal cycling, and the tubes were 
placed in a Perkins Elmer Cetus DNA Thermal Cycler. The 
samples were passed thirty times through a cycle of successive 
incubation steps: denaturation at 94 degrees Celsius for 45 
seconds, annealing at 55 degrees for 45 seconds, and extension 
at 72 degrees for two minutes. After the cycling was 
complete, 5 microl. of the reaction mixture was drawn up and 
run on a 4% agarose gel with a KB ladder serving as a 
standard. The gel was then stained in ethidium bromide for 45 
minutes (Figure 3b). 
DNA Extraction of Remaining ViraPap Specimens 
Once the assay was optimized, we applied the technique to 
patient specimens. To provide an accessible, concentrated DNA 
template, a DNA extraction was carried out on the remaining 
aliquot of the original ViraPap specimen. A protocol for 
extracting sample DNA from transport medium for Southern blot 
analysis was provided by Life Technologies, Inc. This 
protocol was followed with minor modifications. 
A 250 ul. aliquot of each of the original cytology 
specimens (or as much as was remaining) was transferred to a 
1.5 ml. Eppendorf tube. Kit positive controls were also 
processed in the same manner. If less than 250 ul. of specimen 
was available, the sample was augmented with ViraPap transport 

70 
medium. An equal volume of phenol/chloroform/isoamyl alcohol 
(water-saturated and neutralized) was added and the mixture 
vortexed for 10 seconds. The specimens were then centrifuged 
in a microfuge (12,500 x g) at room temperature, and the 
resultant aqueous upper phase transferred to a clean 
Eppendorf. The lower phenol/chloroform phase was reextracted 
with 250 ul. of TE (10 mM This-HCl, pH 7.5, 1 mM EDTA) , 
vortexed, centrifuged, and the upper aqueous phase pooled with 
the previously separated phase. 500 ul. of chloroform/isoamyl 
alcohol (49:1) was added to these pooled phases, and the 
mixture vortexed, then centrifuged for 1 minute, 12,500 x g., 
at room temperature. The resultant upper aqueous phase was 
transferred to a clean Eppendorf, and 50 ul. of 2.75 M NaAc 
and 600 ul. of isopropanol were added. This mixture was 
vortexed, and then centrifuged for 30 minutes in a microfuge 
(12,500 x g) at 4 degrees Celsius. When the centrifuging was 
complete, the supernatant was drawn off, and the tube contents 
were allowed to dry overnight at 37 degrees. In most cases 
there was a visible DNA pellet. The pellet was then 
resuspended in 50 ul. of TE. Five microliters of each 
specimen were passed through the PCR with primers HPV16-1, 
2, 3, and 4; producing amplification products corresponding 
to the E6, E7 and E6E7 targets. Figure 4 shows the results of 
the E6 amplifications. 
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Restriction Digest on Specimens Identified as 16/18 Positive 
by Either ViraType or PCR 
The type 16 and type 18 genomes were entered into the 
Wisc-5 program and a map was produced indicating sites of 
restriction enzyme cutting. The regions corresponding to the 
E6 amplification product were examined within each genome; for 
each type,one enzyme was selected which cleaved the DNA within 
that region, but which had no activity in the alternate type. 
Taq I (manufactured by Bethesda Research Laboratories [BRL]) 
was selected as the type-16 specific enzyme; Taq I recognizes 
a site within the type-16 DNA sequence corresponding to the 
E6 amplification product which would be expected to yield two 
fragments of 134 and 49 nucleotides. Hae III (BRL) was chosen 
as the type 18 specific enzyme; this enzyme would be expected 
to produce two fragments 139 and 63 nucleotides long. 
All the specimens ViraType-positive for type 16/18, as 
well as any specimens which had produced a discernable E6 
amplification product by PCR were included in this experiment. 
Also subjected to restriction digest were all three positive 
ViraType controls, a 10"4 dilution of pBR322-HPV-16 plasmid, 
a negative control (master mix), and one 31/33/35-positive and 
one 6/11 positive specimen. Using the PCR with primers HPV16- 
1 and HPV16-2, new E6 amplification product was made from each 
specimen in preparation for the restriction digest 
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experiments. Five microliters of the resultant products were 
run on a 4% agarose gel for one hour at 100 volts, and the DNA 
stained with ethidium bromide. The specimens could be easily 
grouped into those which produced a bright, easily discernible 
signal, and those with a fainter band at the appropriate 
position. In the subsequent digest, 5 ul. of the former 
specimens were entered into the digestion, while 10 ul. of the 
latter specimens were used. 
5 or 10 ul. of PCR product, 1 ul. of TaqI, 2 ul. of 
buffer (React 2), and water were mixed in a .5 ml. Eppendorf 
to bring the volume of the reaction mixture to 13 ul. The 
samples were allowed to incubate overnight in a 37 degree 
water bath. The entire specimen was then run on a 4% agarose 
gel at 100 volts for approximately two hours and stained with 
ethidium bromide (figure 5a). 
This procedure was then repeated using Hae III, the type- 
18 specific enzyme (figure 5b). 
Determination of Specimen Adequacy 
We developed a random primed genome probe for human DNA 
with the intention of determining whether human DNA was 
present in all the samples. Because of their easy 
accessibility, white blood cells were selected as a source of 
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DNA for creating a probe as well as a target with which to 
test probe sensitivity. 
The target DNA consisted of known dilutions of white blood 
cells processed in a manner mimicking the ViraPap protocol for 
endocervical specimens. The buffy coat was isolated from 1 and 
1/2 ml. of whole blood with a (Ficoll-Pague and PBS gradient) . 
The white blood cells were then washed with five volumes of 
PBS and centrifuged at 7 x g. for five minutes. This wash was 
repeated, and the final supernatant was decanted, leaving 1 
and 1/2 ml. A 100 ul. aliguot of the white cell solution was 
then read in a Ortho Diagnostic Laser cell counter; the white 
cell number was calculated to be 0.9 cells/ul. The solution 
was centrifuged, and the pellet was then resuspended in 1.5 
ml. of the ViraPap transport medium. Two drops of the Sample 
Preparation Reagent were added and a serial dilution was made 
corresponding to 2.25 x 105, 1.125 x 105, 1.125 x 104, 1.125 
x 10 , 1.125 x 102, and 1.125 x 10^ cells. Each dilution, in 
a 250 ul. aliquot, was then applied to a nylon membrane using 
the ViraPap Filter Manifold in the same manner used in loading 
patient specimens. After filtration the membrane was baked at 
55 degrees for 5 minutes and then exposed to ultraviolet (302 
nanometer wavelength) for five minutes to cross link any 
unbound DNA. 
In preparing the probe, white blood cells were isolated 
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from whole blood by the same method described above, and 
■ • 32 labeled by incorporating P labeled adenosine triphosphate 
using denatured WBC DNA as a template. The labeling was 
• • • TM 
carried out using the Pnmagene labeling system, which 
employs a mixture of random hexanucleotides to prime DNA 
synthesis in vitro. 
The isolated white cells in solution were centrifuged, 
and the pellet was resuspended in 0.45 ml.Proteinase K Digest 
with 50 ul. of Proteinase. The mixture was incubated at 55 
degrees for 1 and 1/2 hours to assure digestion, and then a 
DNA extraction was performed using the Chloroform/Phenol 
method described earlier for DNA extraction from ViraPap 
cytology specimens. The WBC DNA product was washed with 
ethanol, dried overnight, and resuspended in 25 ul. of TE. A 
calculation of DNA content was made using spectrophotometer 
measurements, and a volume estimated to contain 25 nanograms 
(ng.) of DNA was entered into the Primagene assay. 
25 ng. of WBC DNA dissolved in TE (lx) were denatured by 
heating at 95 degrees for 2 minutes. The sample was 
immediately placed on ice to prevent reannealing, and the 
Primagene reaction mixture was assembled. The components of 
the Primagene system include a "labeling buffer" which 
contains a mixture of random hexanucleotides which will serve 
as primers for DNA synthesis, a mixture of unlabeled 
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nucleotides, A, T, G, and C, and Klenow enzyme, a DNA 
32 polymerase. P labeled Adenosine was chosen as the labeled 
nucleotide (50 microcuries, 3000 curies/mmole). 10 ul. of 
labeling buffer, 2 ul. of nonlabelling dNTPs, 1 ul. of 
denatured WBC DNA template, 2 ul. of nuclease-free BSA, 5 ul. 
32 
of P-dATP, 5 units of Klenow enzyme, and 25 ul.of sterile 
water were added to a microcentrifuge tube, mixed gently, and 
allowed to incubate at room temperature for 1 hour. The 
reaction was terminated by heating at 95 degrees for 2 minutes 
and subseguent chilling. EDTA was added to 20 mM, and the 
probe was stored at -20 degrees. 
The probe was initially tested against the membrane 
prepared with known dilutions of whole WBCs. The membrane was 
placed in a "seal-a-meal" bag with 15 ml of prehybridizing 
solution containing salmon sperm DNA, and incubated overnight 
• . • 32 in a 55 degree waterbath. 5 ul. (5 microcuries) of ^P-dATP 
were added, and the solution was allowed to hybridize for 48 
hours. The hybridization solution was decanted and the 
membrane was washed twice with a low stringency buffer (Wash 
#1, 2 x SSC/0.1% SDS), at room temperature, for 10 minutes. 
The membrane was then washed with a slightly more stringent 
buffer (Wash #2, lx SSC/0.1% SDS) at room temperature for 30 
minutes. The membrane was blotted dry and placed in a film 
cassette with Kodak film and intensifying screens, and was 
allowed to expose for 7 days (figure 6). 
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The ViraPap membranes were stripped of previous RNA probes 
by a shaking incubation at 90 degrees with a high stringency 
wash (50% Formamide). The membranes were subseguently washed 
twice with a low stringency wash for 10 minutes at room 
temperature. Prehybridization of the membranes was carried out 
. 3 2 
overnight at 55 degrees, and 5 ul. of P labeled probe were 
added to the solution in the morning. After a 24 hour 
incubation, the membranes were washed with Wash #1 and Wash 
#2 as described above, and the membrane was placed in a film 
cassette with intensifying screens. The film was allowed to 
expose for 6 hours at -70 degrees (figure 7). 
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RESULTS 
Chart Review 
Forty gynecologic oncology charts were reviewed in this 
portion of the study. Parity at the time of specimen 
collection was reviewed, and 18 of 40 (45%) of the subjects 
were found to be nulliparous, 14 of 40 (35%) were parous, 7 
(17%) were pregnant. For 1 subject there was no parity 
documented. 
Twenty-one of the 40 cervical smears (Pap smears) taken 
at the time of ViraPap specimen collection were noted to have 
abnormal findings (53%). Of these, 10 were described at 
showing atypia or "koilocytic atypia," and 11 smears were read 
as displaying some degree of dysplasia or CIN 1, 2, or 3. The 
remaining 19 Pap smears were read as normal. 
Of those subjects who had abnormal findings on pap 
smears, 11 (55%) had positive ViraPap tests. There were 5 
cases in which a normal pap smear was accompanied by a 
positive ViraPap test. In all of these cases there was 
evidence of disease by other parameters (cervical biopsy or 
colposcopy.) 
When cervical biopsy pathology was examined, there were 
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19 patients with evidence of disease ranging from koilocytic 
atypia to invasive Ca. The ViraPap test detected HPV DNA in 
the endocervical swab specimens of 9 (47%) of these cases. 
There were 10 cases of cervical pathology for which the 
ViraPap test was negative. There were, however, 9 subjects in 
whom cervical biopsy was not performed despite abnormal 
findings on colposcopy. The ViraPap detected HPV DNA in 4 of 
these cases, 1 of which had a normal accompanying Pap smear. 
Interestingly, there was one case in which a positive ViraPap 
test was obtained despite a normal cervical specimen: this 
patient had also had a vaginal biopsy performed, and this 
proved to be positive for dysplasia. Another subject had both 
negative ViraPap and cervical biopsy results, but had a 
vaginal biopsy which showed koilocytic atypia. Both these 
subjects had normal Pap smears. 
With one exception, all the patients in the study had a 
Pap smear taken at the time of ViraPap specimen collection. 
The exception was a patient who was evaluated at the 
gynecologic oncology clinic, with simultaneous referral to 
the Pathology department of previously taken biopsy specimens 
showing invasive cancer. This patient had a nodular, cancerous 
cervix visible on gross inspection, and no Pap smear was 
taken. For the purposes of this study, this patient was scored 
as having had a positive Pap smear because her cervical 
disease would have been evident to any clinician taking a Pap 
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smear. 
In this study, cervical biopsies were not obtained in 
a number of instances in which there were colposcopic findings 
suggestive of disease. There were two reasons biopsy was not 
carried out; first, several of the patients were pregnant, and 
cervical biopsy was thought to pose an unnecessary risk, and 
second, a number of patients had had previous colposcopic and 
histologic evaluation before presenting to the YNHH 
gynecologic oncology clinic, and had their pathology specimens 
referred and reread by the Yale Pathology department. When 
these specimens showed evidence of disease, it was sometimes 
not necessary to repeat biopsies as it was not felt that the 
information provided would alter management. Because these 
biopsies were not obtained at the same time as the rest of 
the material analyzed in this study, the findings were not 
included in our data. 
ViraPap Results 
Any specimen whose signal was equal to or of greater 
intensity than the signal corresponding to the kit low 
positive control was considered to be positive. A positive 
result indicates the presence of HPV DNA of at least one of 
types 6, 11, 16, 18, 31, 33, and 35. ViraPap kit protocol 
recommends that a specimen which yields a signal which is more 
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distinct than the negative control, but less than the low 
positive control should be considered "borderline" and that 
another specimen be obtained from that patient, and the assay 
repeated. 
Sixteen of 40 specimens (40%) tested positive for the 
presence of HPV DNA of types 6, 11, 16, 18, 31, 33, or 35. 
Many of the autoradiograph signals produced by the samples 
were of far greater intensity than even the high positive 
controls, and there was virtually no background. (note: The 
signal produced at position A3, corresponding to specimen #8, 
was thought to represent a rim of HPV DNA-positive fluid drawn 
over from the adjacent, highly positive specimen (#13). This 
specimen was not counted among the positives, and was 
subsequently established to be negative.) 
The ViraPap protocol includes a disclaimer with regard 
to bloody specimens, stating that "blood may cause false 
negative results." Six specimens among the total 40 had been 
noted to be dark yellow or brown at the time of ViraPap assay, 
suggesting the presence of blood in the solution. Only one of 
these, #40, resulted in a positive ViraPap test (figure 1) . 
ViraType Results 
Each of the three membranes represented a different viral 
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group typing. Any signal generated by a patient specimen 
which was equal to or less intense than the kit negative 
control was interpreted as negative; a relative absence of HPV 
DNA of the type being probed for on that particular membrane. 
A signal of greater intensity than the negative control was 
scored as positive. If a patient specimen produced a signal 
greater than the negative control on more than one membrane, 
the possibility of infection with multiple types of HPV was 
considered, and interpreted in light of the potential cross 
reactivity described below. 
Interpretation of the ViraType autoradiograph was a 
straightforward process confounded only by slight cross 
reactivity between the positive controls for types 16/18 and 
31/33/35. A region of homology between type 16 and type 31 
allows for some cross-reactivity between these probes when 
large amounts of HPV DNA are present. For this reason, a 
specimen strongly positive for HPV DNA of types 16/18 may show 
a signal on the 31/33/35 membrane as well. If the signal on 
this second membrane is of equal or lesser intensity than the 
31/33/35 positive control on the 16/18 membrane, cross¬ 
reactivity, and not a true 31/33/35 positive should be 
suspected. It was not possible to determine whether more than 
one viral type within a viral group was present, as the 
ViraType probes were mixtures of different viral types. 
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In all, 21 specimens were assayed with the ViraType kit. 
Of these, 16 had previously tested positive with ViraPap. Of 
the 16 specimens, 1 was typed as 6/11; 6 were typed as 16/18; 
6 were typed as 31/33/35; and 2 specimens (#17 and #28) 
appeared to have multiple infection with HPVs from groups 
16/18 and 31/33/35, as these specimens had a strongly positive 
result on the 16/18 membrane, and also produced a signal on 
the 31/33/35 membrane of greater intensity than the 
corresponding control on the 16/18 filter. One specimen (#40), 
which had produced a positive signal by ViraPap, did not 
produce a positive signal on any one of the three viral-group 
membranes, and hence was interpreted as "untypeable". The 
additional 5 specimens assayed by ViraType included 2 used as 
internal negative controls (#22,25), a third questionable 
specimen (#8), and two specimens not previously run on 
ViraPap, (#45,and 46). All five of these additional specimens 
had a negative result by ViraType assay (figure 2). 
PCR Results 
The prime objective in carrying out the Polymerase Chain 
Reaction was to verify HPV type 16 positive specimens by a 
very sensitive means, and to identify any additional positives 
not detectible by the nucleic acid hybridization methods 
already used. The ViraType assay does not differentiate 
between types 16 and 18, so starting samples were known only 
X 
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to be 16/18 positive. 
When the polymerase chain reaction was carried out on the 
serial dilutions of pBR322-HPV16 plasmid, clearly defined 
bands were seen at the predicted molecular weights. Primers 
HPV16-1 and HPV16-4, which flank a stretch of genome including 
both E6 and E7, produced a 398 nucleotide amplification 
product from dilutions as high as 10 (-7). Primers HPV16-1 and 
HPV16-2 produced a 183 nucleotide amplification product with 
equal sensitivity. The E7 amplification product, flanked by 
HPV16-3 and HPV16-4 was visible from a starting dilution of 
10 (-6). This last reaction series was of interest because of 
the formation of "primer-dimers" by oligonucleotide primers 
not consumed in the amplification reaction (Figure 3b). 
The study samples were divided into two sets and 
subjected to the PCR. The first reaction series included four 
specimens which had tested negative by ViraPap and were not 
believed to contain any HPV DNA, the six specimens identified 
as type 16/18 by Viratype, the two specimens demonstrating 
coinfection, as well as one 6/11-positive specimen, and two 
31/33/35 specimens. DNA extracted from the three kit controls 
for 6/11, 16/18, and 31/33/35 was also included. 
All the specimens identified as type 16/18 by ViraType 
produced a discernable band at the position of the E6 product 
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when amplified using the HPV16-specific primer for E6. Neither 
the four specimens originally negative by ViraPap, nor the 
type 6/11 specimen produced a positive result. One of the 
31/33/35-positive specimens (#44) gave a weakly positive 
signal, while the other did not. DNA extracted from the kit 
controls for type 16/18 gave a strongly positive band on the 
gel, and the kit control for type 6/11 produced a weakly 
positive result. The kit control for types 31/33/35 did not 
produce a visible signal. 
The second reaction series was not known to include any 
specimens containing HPV 16/18 DNA. Four additional positive 
specimens were readily identifiable after PCR. Two of the four 
were strongly positive; one specimen (#40), had been 
previously categorized as "untypeable" following a positive 
ViraPap result and negative ViraType test, and the other had 
been negative by both ViraPap and ViraType testing. The 
remaining two positive specimens (#s 21,22) could be 
considered weakly positive, and produced bands with an 
intensity equal to or less than that of the 6/11 control on 
the first gel (Figure 4). 
Results; Restriction Digest 
Subjecting the specimens to the PCR identified several 
additional 16/18 positive specimens. While the oligonucleotide 
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primers used in the PCR were designed with type 16 specificity 
in mind, all the specimens identified as 16/18 positive by 
ViraType had also been successfully amplified by the PCR, so 
the primer set’s ability to differentiate between type 16 and 
18 by preferentially binding to type 16 sequences had not been 
demonstrated. A restriction digest with type-specific enzymes 
was undertaken to differentiate between type 16 and type 18 
positive specimens as a means of ascertaining primer 
specificity. 
Taq I cut all the 16/18 positive specimens (as identified 
by ViraType and /or PCR), producing visible fragments of 
approximately 140 nucleotides in length, as predicted by 
restriction mapping of HPV type 16. The specimens which had 
been weakly positive by PCR (17, 21, 22, 44, and C-l) were 
indistinguishable after digestion (Figure 5a). 
Digestion with HAE III, the type 18 specific enzyme, did 
not result in any alteration in fragment size from uncut form. 
The PCR weak positives were still faintly visible at a 
position corresponding to their uncut molecular weight (Figure 
5b) . 
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Results; Sample Adequacy 
The ViraPap kit uses probes which are capable of 
detecting the DNA of HPV types 6/11, 16/18, and 31/33/35 only. 
When a specimen is assayed and a negative result is obtained 
no inference can be made with regard to the possibility of 
infection with another type of HPV, nor can one be assured 
that an adequate specimen was initially obtained from the 
patient. Generally. 10-100 labelled copies will produce a 
autoradiographic signal. This number is thought to represent 
the lower limit of resolution by this technique. 
Use of the human DNA probe on known dilutions of white 
blood cells demonstrated that the probe was capable of 
detecting as few as (1000) cells after a seven day exposure. 
When the probe was applied to the ViraPap membranes and 
allowed to expose for 6 hours, every patient specimen produced 
a signal darker than the high positive control, known to 
contain 2 x 105 disrupted Hela cells. The intensity of the 
signal produced by a given specimen with the human DNA probe 
did not correspond to the signal intensity of the same 
specimen when probed with either the ViraPap or ViraType 
probes (Figure 7). 
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DISCUSSION 
Subjects 
The patients in this study could all be considered to have 
a risk factor for the later development of cervical cancer on 
the basis of a previously abnormal Pap smear. Information 
concerning age at first coitus, number and health status of 
sexual partners, and histories of sexually transmitted 
diseases was not universally reported in the gynecologic 
oncology records, and hence could not be analyzed in a further 
consideration of risk status. A large proportion (17%) of the 
patients were pregnant; as discussed previously, pregnancy may 
be considered an altered state of immunity and may lead to a 
reactivation and increased rate of viral production. For these 
reasons, the patients in this study are not representative of 
the general population and the results of this study must be 
interpreted with reference to a "high risk" population. 
While most of the oncology records recorded number of 
sexual partners, and it can be assumed that if a patient had 
not been sexually active, this fact would have been recorded 
as remarkable, there was not universal documentation of 
virginal/nonvirginal status among the study patients. In light 
of recent anecdotal reports of HPV transmission to the 
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genitals without sexual contact, future studies with a patient 
population referred for abnormal cervical cytology might 
investigate sexual activity. 
ViraPap and the Pap Smear 
Studies assessing a detection method must choose some 
standard definition of disease by which to measure the new 
test's sensitivity. Most investigations of hybridization 
methods for HPV DNA detection have used histopathologic 
evidence of disease as the standard for comparison. In this 
study, all abnormal findings on Pap smears, ranging from 
koilocytic atypia and other cytologic findings suggestive of 
HPV infection, to CIN3 were taken to represent "cervical 
disease". Such a broad classification system, while failing 
to distinguish between simple viral infection and CIN, is 
acceptable in this investigation because all the specimens 
thereby included warrant follow-up and further diagnostic 
interventions such as colposcopy and cervical biopsy. 
Overall, cytologic methods (Pap smear) detected cervical 
disease with the greatest frequency. Twenty-one of the 40 Pap 
smears obtained on the day of study (52.5%) showed evidence 
of disease as defined above. It is of note that all (100%) of 
the subjects in this study were referred for an abnormal Pap 
smear in the recent past, thus highlighting the limitations 
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of relying on the Pap smear alone to demonstrate disease. The 
Pap smears with cytologic abnormalities were not necessarily 
those found to contain HPV DNA; 11/21 of the abnormal Pap 
smears (52%) were positive for the presence of HPV DNA. 
The ViraPap detected HPV DNA in 16/40 (40%) of 
concurrently taken endocervical swabs. The specimens in which 
HPV DNA was detected were not necessarily those which showed 
cytologic abnormalities; Most significantly, 5/19 (26%) of 
the cytologically normal Pap smears were found to contain HPV 
DNA. These latter specimens represent five instances in which 
a woman with an increased risk of developing cervical cancer 
may have failed to be identified. Typing of the virus found 
in these five instances revealed four infections with the 
"high risk" group, types 16 and 18, and one infection with the 
group 31/33/35, which is associated with an intermediate risk 
of developing cervical neoplasia or a precursor lesion (20, 
26, 27, 28, 64). When the four 16/18-positive specimens were 
subjected to PCR and restriction digestion, they were 
ascertained to be type 16. It is significant that these five 
cases all had evidence of disease by another more invasive 
parameter (cervical biopsy, or colposcopy). Colposcopy and 
biopsy are not performed in routine screening, so those 
patients with normal Pap smears may have been missed by 
ordinary screening methods, but were identified as harboring 
HPV DNA by the ViraPap test. 
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A single pathologist (S.F.) was asked to rescreen the 40 
Pap smears obtained on the day of study; while he was aware 
of the purposes of this study, S.F. did not have any knowledge 
of the previous interpretation given the Pap smears, nor did 
he know of the ViraPap results for each patient. Because the 
rescreening was not carried out in a completely blind manner, 
calculations of interobserver variability would not be 
accurate. Nonetheless, an important finding emerged from the 
rescreening efforts; in the 5 cases in which a negative Pap 
smear had a corresponding positive ViraPap test, 4 of the Pap 
smears were described as inadequate on review. Two smears were 
described as unsatisfactory because of the absence of 
endocervical cells, one was of unacceptable quality as a 
result of airdrying, and one had obscuring purulence and 
cytolysis. The fifth smear, considered adequate, was read as 
CIN3 on rescreening—it had been interpreted as normal on 
initial evaluation. These findings serve to highlight the 
importance of specifying "sample adequacy" when reporting 
cytology interpretations, and also demonstrate the role that 
an HPV DNA detection test such as ViraPap could play in 
identifying patients in need of further evaluation. 
A positive ViraPap was found to be a good predictor of 
the presence of cytologic abnormalities. In 11/16 (69%) of 
instances in which HPV DNA was detected, cytologic 
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abnormalities were present, ranging from atypia to CIN3. The 
ViraPap appeared more sensitive in the detection of dysplasias 
than in cases of atypical cytology. Six of 7 (86%) of patients 
with CIN 1, CIN2, or CIN3 had HPV DNA detected by ViraPap, 
while in only 4/13 (31%) of patients with atypia, or 
condylomatous changes, was HPV DNA detected. Because of the 
small number of specimens in each of these categories, actual 
sensitivities were not calculated. 
There were 10 cases of abnormal Pap smears in which HPV 
DNA was not detected by ViraPap. In nine of these cases there 
was evidence of disease by another parameter, either tissue 
biopsy or colposcopy. In one case neither biopsy or 
colposcopy was performed for reasons which are not clear. 
These 10 specimens could be considered false negatives. If a 
false negative rate is calculated, taking as the numerator 
those cases in which disease is present but HPV DNA is not 
detected by ViraPap, and as the denominator, all cases in 
which disease is present as shown by cytologic examination, 
a value of 46.7% is obtained. This is slightly better than 
some of the estimates of false negativity rates for the 
detection of cervical disease by Pap smear (86). The factors 
contributing to the high rate of false negative Pap smears has 
been discussed in some detail (see section on the Pap smear). 
There are a number of reasons a ViraPap test could yield a 
false negative result. First, the ViraPap only contains HPV 
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RNA probes complementary to the DNA of types 6, 11, 16, 18, 
31, 33, and 35, and the assay is run under highly stringent 
conditions. Any other types of HPV will not be recognized by 
the probes, and thus will be undetected in this test. 
Heretofore unidentified HPV types are unlikely to hybridize 
under the stringent conditions used, even with significant 
homology. Second, an extremely low level of infection with few 
copies of HPV DNA, may escape detection by this test. The low 
positive control provided in the kit contains 4 x 10 (4) 
disrupted Hela cells, which each contain (10) copies of 
integrated HPV DNA per cell. This is the lower limit of 
detection representative of HPV infection as guaranteed by the 
kit manufacturers. Samples containing less HPV DNA than that 
in the low positive control may not be detected by the test. 
Third, the specimen obtained for analysis may not be 
representative of the actual cervical pathology. As with the 
Pap smear, these specimens are subject to a variety of 
"sampling errors". While using a probe for human DNA can 
assure us that a sample of appropriate quantity was obtained, 
we can make no assumptions about whether the transformation 
zone or any potential lesions on the cervix were sampled. 
Unlike the Pap smear, with which the presence or absence of 
endocervical cells can be used to assess for adequate 
sampling, with this assay we are limited to an assessment of 
specimen quantity. 
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Finally, according to the kit manufacturers, bloody 
specimens may yield false negatives. Six of the specimens in 
this study were considered "bloody” at the time of testing. 
Only one of these yielded a positive result by ViraPap, but 
four of the remaining five had abnormal cytology on the 
accompanying Pap smears. Had they been less bloody, HPV DNA 
may have been detected in these specimens; were these samples 
to be eliminated from the false negatives, the false negative 
rate would improve to 28.6%. 
A molecular diagnostic test should not be allowed to 
substitute for clinical judgement. There were two instances 
in this study in which a vaginal biopsy was obtained. In both 
cases, the subject had a normal Pap smear and a cervical 
biopsy without evidence of disease on the day of study, but 
a vaginal biopsy which showed disease—koilocytic atypia in 
one case, and mild dysplasia in another. Only one of these 
subjects had HPV DNA detected by ViraPap. While these are only 
two examples, these disparate findings suggest that HPV DNA 
may move freely enough within the genital tract (in 
desguamated cells, etc.) to be picked up by a swab at a 
location other than the infected site. These findings should 
also serve to caution the clinician against a reliance on 
molecular diagnostic tests as a substitute for other means of 
evaluation. 
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The results of this study are similar to those found in 
other studies comparing cytologic evidence of disease with the 
detection of HPV DNA by hybridization methods. Morse et al. 
conducted a study using high stringency dot blot hybridization 
to detect HPV DNA in specimens obtained from 164 cervical 
scrapes (Ayre spatula) obtained from 143 women (27). The 
authors of this study classified smears showing CIN 
separately from those simply showing evidence of viral 
infection. 
HPV DNA was detected in 64 (39%) of the specimens, while 
cytologic features suggestive of HPV infection were found in 
67 (41%) of smears. As was the case in the present study, the 
same specimens did not necessarily contain both cytologic and 
hybridization-based evidence of disease. Sixteen (10%) of the 
samples which had normal cytology were found to contain HPV 
DNA. Our study showed a substantially higher percentage of 
such cases (25%) . One explanation for this discrepancy is that 
specimens in our study were obtained from a "high risk" 
population, with a higher expected disease prevalence. The 
subjects in Morse's study were not preselected to be "high 
risk", although the high rate of abnormal cytologic findings 
and HPV DNA detection may suggest otherwise. There were 19 
cases in which there was cytologic evidence of HPV infection, 
but no HPV DNA detected by hybridization. This yields a false 
negative rate of 28%, which may be explained in part by the 
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fact that the investigators used probes to only three 
different types of HPV; types 6,16, and 18. 
When the specimens showing CIN were considered, 30/40 
(75%) were found to harbor HPV DNA; 5 contained HPV type 6, 
and 21 contained HPV type 16. The hybridization test seemed 
to be a good indicator of infection in this group, as 27/30 
(90%) of the HPV DNA-positive specimens showed evidence of HPV 
infection. 
Another study which compared findings on Pap smears to 
the results of an HPV DNA hybridization test used 
cervicovaginal lavage as means of collecting the specimen for 
hybridization studies (26). Burk et al. carried out a 
prospective study of 60 women referred to a colposcopy clinic 
because of a previously abnormal Pap smear. Following the 
collection of a Pap smear, the cervix was swabbed with a 
normal saline solution, followed by 5% acetic acid. The cervix 
was then lavaged with 7-8 ml. of saline solution, and the 
washings aspirated from the posterior vaginal fornix. The 
solution was centrifuged, and a DNA extraction was performed 
on the sedimented cells. Southern blot analysis was carried 
out, and the membranes were probed with HPV types 6, 11, 16, 
and 18. 
On the day of study, 28/60 (47%) of the women had an 
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abnormal Pap smear, and 32/69 (53%) had normal cytology. 21/28 
(75%) of patients with ClassII-IV smears had HPV DNA detected 
by Southern blot on cervicovaginal lavage specimens. Of the 
32 women with negative Pap smears, 9 (28%) had HPV DNA 
detected. A retrospective review of the Pap smear results 
within a one year period for this group of patients revealed 
that 6/9 (67%) had had a Class III or Class IV smear in 
previous or subsequent specimens. Amongst the 30 patients who 
tested positive for the presence of HPV DNA, 21 (70%) were 
found to have cytologic abnormalities; HPV detection by 
Southern analysis on lavage specimens was predictive of a 
dysplastic cervical lesion in at least 95% of the patients 
who underwent colposcopically directed biopsy. Pap smears done 
on the day of study detected only 68% of these biopsy-proven 
dysplasias. There were 7 patients in whom HPV DNA was not 
detected, but whom were found to have ClassII-IV smears. A 
false negative rate of 25% can be calculated for the HPV DNA 
detection method using the Pap smear result as the indicator 
of disease. Among the Pap smears showing cytologic 
abnormalities,(ClassI-IV) , typing revealed type 6 in 2 cases, 
type 11 in 2 cases, type 16 in 7 cases, type 18 in 5 cases, 
mixed infection with types 11 and 18 in 1 case, and 4 cases 
with an unidentified type. 
McNichol et al. used the filter in situ hybridization 
method to detect the presence of HPV DNA in cellular specimens 
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obtained from the Ayre spatula and endocervical swab after 
preparation of the Pap smear (28) . In a patient population of 
98 women referred to colposcopy clinic for a previously 
abnormal Pap smear, the authors detected HPV DNA of types 
6/11/16 or 18 in 79(81%) of the specimens. Only 30 (31%) of 
the women had HPV infection recognized by cytologic means. The 
authors conclude that filter in situ hybridization is far more 
sensitive than cytology as means of recognizing HPV infection, 
and recommend that such a method be used to augment present 
Pap smear screening. 
Differences in study design make a direct comparison 
between the results from these studies and our own impossible. 
There were some similarities; Burk et al. and McNichol et al. 
selected a patient population very similar to that in our 
study. Like our study, all three of these studies were 
designed in a prospective fashion, and included some 
comparisons between cytology specimens and hybridization 
methods as a means of detecting HPV infection. However, in 
each study the methods of sample collection and hybridization 
were different, and this may have affected the results 
substantially. A comparison of the sensitivities of HPV DNA 
detection cannot be made directly between these 
investigations. 
Despite the differences in methodology and patient 
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population, one finding has emerged consistently from these 
and other studies; the use of hybridization techniques has 
identified HPV DNA in a large proportion of specimens found 
to be abnormal by other means (cytology, histopathology, or 
colposcopy) . In addition, HPV DNA has been found in a 
significant percentage of samples otherwise considered to be 
free of disease. The sensitivity of HPV detection is clearly 
not high enough to justify abandoning the Pap smear, but 
detection of HPV DNA may assist in the interpretation of an 
otherwise normal smear. 
Typing 
Determinations of the viral type found in different 
lesions has provided a great deal of information on the tissue 
tropism, prevalence, and apparent oncogenic potential of 
various forms of HPV. On the basis of such typing studies 
"high risk" and "lower risk" HPV types have been suggested. 
The clinical utility of knowing the viral type with which a 
patient is infected has not yet been established. The ultimate 
usefulness of this technique will be determined by whether or 
not a knowledge of viral type affects patient management. 
Conceivably, infection with HPV-16, the type most highly 
associated with cervical carcinoma, could lead clinicians to 
recommend that a patient pursue more frequent monitoring of 
cervical cytology, or further diagnostic measures to assure 
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the absence of cervical disease. On a research level, viral 
typing continues to be an important way to study the 
oncogenicity, and to follow trends in the epidemiology of this 
genus of viruses. 
In this study typing was performed on the specimens which 
had produced a positive result by ViraPap. These 16 specimens 
were predominantly of types 16/18 (6) , and types 31/33/35 (6) . 
There was one specimen of type 6/11, two instances of 
coinfection with types from groups 16/18 and 31/33/35, and one 
specimen which was untypeable by the ViraType method. 
There was some variation in the degree of cytologic 
abnormality associated with different viral groupings. The 
specimen typed as 6/11 had a corresponding Pap smear 
interpreted as koilocytic atypia. The specimens typed as 16/18 
had corresponding smears read as negative (4), CIN2 (1), and 
CIN3 (1). Smears corresponding to the type 31/33/35 specimens 
were interpreted as negative (1), koilocytic atypia (2), 
ungraded CIN (1), CIN2 (1), and CIN3 (1). The coinfected 
specimens had corresponding Pap smears of CIN2 and CIN3. 
The sample size in this study is too small to analyze for 
type associated trends. An investigation of viral types found 
in different grades and kinds of cervical malignancy would 
ideally select specimens in both a retrospective and 
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prospective fashion, have a large sample size, and use 
multiple probes with both high and low stringency conditions 
to allow for the identification of new viral types. 
Polymerase Chain Reaction 
All the specimens in this study were carried through the 
polymerase chain reaction using HPV type 16 specific primers. 
All the specimens which had been identified as type 16/18 by 
ViraType testing produced an E6 amplification product. This 
finding suggested that HPV type 16 was present in all six 
specimens, but provided no information concerning type 18. 
Restriction analysis with a type 16 specific enzyme 
demonstrated that the PCR products were in fact amplifications 
of the type 16 E6 ORE. While this confirms the specificity of 
the amplification primers used, no conclusions can be drawn 
regarding the additional presence or absence of type 18 in 
the specimens. 
Four additional specimens which had not been previously 
identified as containing HPV DNA produced amplification 
products. Two of the samples produced strong signals equal 
in intensity to those of the known 16/18-positive specimens. 
One of these samples (#33) had tested negative with the 
ViraPap screen, subsequent typing was not done. This subject 
had a normal Pap smear on the day of study; a corresponding 
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cervical biopsy showed koilocytic atypia, and colposcopy had 
revealed a characteristic punctate lesion extending into the 
endocervical canal. Thus, this specimen had evidence of HPV- 
related disease by two other parameters, but had escaped 
detection by both cytologic methods and the ViraPap screening 
test. 
Specimen #40 yielded a positive ViraPap result, but had 
not hybridized with any of the type specific probes in the 
ViraType kit, and was therefore classified as "untypeable". 
This subject had a nodular cervix on gross inspection, and 
histopathology described as poorly differentiated, invasive 
squamous cell carcinoma. Of note, the endocervical sample from 
this subject had been described as "bloody" at the time of 
collection. 
Given the intensity of the signal produced by the 
amplification products from these two specimens, and the 
evidence of disease by other parameters, it is unlikely that 
contamination is responsible for these results. It is likely 
that the HPV DNA exists in episomal form in the first of these 
cases, and in an integrated form in the invasive carcinoma. 
The fact that amplification proceeded in both these cases 
suggests that the PCR is not limited in its ability to detect 
HPV DNA in its varied states. 
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Specimens #21, and #22 produced weakly positive signals 
after PCR. Neither of these specimens had tested positive by 
ViraPap, but both had evidence of disease by Pap smear, biopsy 
and colposcopy. It is possible that these are examples of 
contamination with PCR fragments. It is unlikely that 
contamination occurred by carry over of raw material from 
other specimens, as the specimens adjacent to these were 
negative by ViraPap testing and show no evidence of 
amplification by PCR. 
One specimen typed as 31/33/35, and the kit control for 
type 6/11 both produced weakly positive amplification 
products. This is of considerable interest in light of the 
fact that comparable specimens (one positive for 6/11 and five 
others positive for 31/33/35) did not give positive results. 
While contamination must always be considered in explanation, 
it is also possible that small differences in the base pair 
sequences within the highly conserved E6 ORF are responsible 
for the failure or success in amplification amongst these 
samples. Such subtle variation might not be evident with 
hybridization techniques using essentially the entire genome, 
but may be asserted when specific oligonucleotide primers are 
used to recognize sequences. 
As described earlier, investigators using the PCR have 
reported detecting HPV DNA in as many as 84% of cytologically 
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normal cervical smears, a majority of dysplastic smears, and 
100% of cervical carcinomas (29). Our study is distinguished 
from this and other studies using PCR by the relatively few 
specimens found to be positive for HPV 16 DNA. Our results 
suggest that when careful technique is observed, and primers 
are designed with specificity to the type being sought, the 
polymerase chain reaction can be a sensitive confirmatory test 
following hybridization studies, and may detect additional 
cases missed by these methods. Whether this labor intensive 
test will become commonly utilized will depend in part on 
whether further studies establish that detection of HPV DNA 
by this means is clinically significant in the absence of 
positive hybridization studies. Subjecting specimens to the 
PCR with a panel of primers specific to the higher risk types 
(16, 18, 31, 33, and 35) may prove useful. 
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CONCLUSIONS 
A number of investigators have described a history of 
previously normal Pap smears in patients presenting with 
invasive cervical carcinoma. Frequently, the patient had a 
normal Pap smear within a year of diagnosis. Although the 
decrease in mortality due to cervical cancer in the United 
States can be attributed in large part to this simple 
screening test, a proportion of women with cervical disease 
are clearly going undetected. 
The association between infection with HPV and cervical 
cancer is very strong. Detailed investigation on the 
molecular level continues to add evidence for its role in 
oncogenesis, and as the likely etiologic agent in cervical 
cancer. 
Hybridization methods and newer amplification techniques 
have demonstrated HPV DNA in cytology and histology specimens 
without any evidence of disease, as well as in all grades of 
CIN and invasive cancer. These detection methods provide means 
of investigating the epidemiology and pathogenesis of this 
virus. Most importantly, they allow for the identification of 
individuals with HPV infection, perhaps leading to closer or 
more frequent monitoring. 
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Until an etiologic role for HPV in cervical 
carcinogenesis is definitively established, the presence of 
the virus can at least be considered a marker for an increased 
risk of developing cervical disease. This study undertook to 
assess the usefulness of applying a hybridization test for 
detecting HPV in conjunction with the Pap smear, as compared 
to a reliance on the Pap smear alone. 
Our data showed that while cytologic examination revealed 
HPV-associated changes and dysplasias most frequently, the 
ViraPap detected HPV DNA in a significant proportion of the 
Pap smears not otherwise identified as abnormal. When the 
viral DNA present in these cases was typed, 80% of the cases 
were found to contain "high-risk" HPV types; the remaining 
case contained an HPV type associated with an "intermediate" 
risk of developing cervical disease. Given the fallibility of 
cytologic screening programs in the recognition of cervical 
malignancies and precursor lesions, we conclude that in a high 
risk population the use of an HPV detection test such as 
ViraPap serves as a useful adjunct to the Pap smear in 
identifying women at risk for developing cervical cancer. 
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APPENDIX 
s# Coord VPap Vtype PCR Pap CBx ECC Colp Preg 
1 2 (D1) _ ND _ _ ND ND _ _ 
2 2 (El) - ND - CIN3 ND ND + - 
3 2 (A2) - ND - + CIN2 ND + + 
5 2(C2)/A2 + 31/33/35 - CIN2 CIN3 CIN + - 
6 2(D2)/A3 + 16/18 + CIN2 CIN3 - + - 
7 2(E2)/A4 + 31/33/35 - + CIN2 ND + + 
8 2(A3)/A5 - - - - ND ND - - 
9 2(B3)/B2 + 31/33/35 - + + ND + + 
10 2 (C3) - ND - + + + + - 
11 2(D3)/B3 + 16/18 + - 
-(*) - + - 
12 2(E3)/B3 + 16/18 + - - + + - 
13 2(A4)/B5 + 16/18 + - ICC ND + - 
14 2(B4)/C2 + 31/33/35 - + ND ND + + 
15 2(C4)/C3 + 6/11 - + + - + - 
16 2(D4)/C4 + 16/18 + - ND ND + + 
17 2(E4J/C5 + 31/33/35 
16/18 
+ CIN2 CIN1 
' 
+ 
' 
18 2(A5)/D2 + 16/18 + CIN3 CIN3 ND + + 
19 2 (B5) - ND - - ND - + - 
20 2 (C5) - ND - - - - + - 
21 2 (D5) - ND + + + - + - 
22 2 (E5)/D3 - - + + + - + - 
23 1 (A1) - ND - - CIN1 - + - 
25 1(C1)/D - - - + CIN2 - + - 
26 1 (Dl) - ND - - "(*) - + - 
27 1 (A2) - ND - - CIN1 - + - 
28 1(B2J/D5 + 16/18 
31/33/35 
+ CIN3 ND ND + 
29 1(C2)/El + 31/33/35 - CIN ND ND + + 
30 1 (D2) - ND - + - - + - 
31 1 (A3) - ND - - ND ND + - 
32 1 (B3) - ND - - ND - + - 
33 1 (C3) - ND + - + - + - 
34 1 (D3) - ND - - ND ND - - 
35 1(A4) - ND - CIN1 ND ND ND - 
36 1 (B4) - ND - - ND ND ND - 
38 1(D4) - ND - + + + - - 
39 1 (E4) - ND - - ND ND - - 
40 1(A5)/E2 + - + + (@) ND ND ND - 
41 1 (B5) - ND - + CIN1 ND + - 
43 1 (D5) - ND - - ND + + - 
44 1(E5J/E3 + 31/33/35 + - + - + - 
Key: S# (Specimen number), Coord (Coordinates;refers to positions 
on ViraPap/ViraType filters), VPap (ViraPap), VType (ViraType), PCR 
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(Polymerase Chain Reaction), Pap (Papanicolaou Smear), CBx 
(Cervical Biopsy), ECC (Endocervical Curettage), Colp (Colposcopy), 
Preg (Gravity at time of specimen collection), ND (Not Done). 
"+" under Pap, CBx, and ECC headings denotes koilocytosis or 
condylomatous changes. 
(*) specimens #11 and #26 both had negative cervical biopsies but 
vaginal biopsies which showed CIN1 and koilocytosis respectively. 
(@) specimen #40 did not have a Pap smear but 
had a grossly nodular cervix, so was scored as positive. 
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(Figure 1) ViraPap Results. Filters #1 (top) and #2 (bottom). The 
high and low positive controls on filter #1 correspond to 
coordinates El and E2 respectively. On filter #2 high and low 
positive controls are at positions A1 and B1 respectively. For 
specific patient specimen information refer to the data listing in 
the appendix. 
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(Figure 2) See legend on following page. 
6/11 
16/18 
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31/33/35 
(Figure 2 continued) ViraType Results. Filters from ViraType 
procedure. Top filter probed with type 6/11 specific probes, middle 
filter with type 16/18 probes, and bottom filter with type 31/33/35 
specific probes. Positive controls can be seen at positions Al, Bl, 
and Cl on the 6/11, 16/18, and 31/33/35 respectively. 
PCR PRIMER SEQUENCES 
PRIMER SEQUENCE STARTING 
BASE PAIR 
HPV16-1 5 ' CAGCAATACAACAAACCGTTGTGTG 3 ' 371 
HPV16-2 5 ' GCTGGGTTTCTCTACGTGTTCTTG 3 ' 554 
HPV16-3 5 ' GCAACCAGAGACAACTGATCTCTAC 3 ' 606 
HPV16-4 5 ' GTACGCACAACCGAAGCGTAGAG 3 ' 769 
(Figure 3a) Nucleotide sequences of the synthesized primers. 

Ill 
E6E7 E6 E7 
(Figure 3b) PCR products using serial dilutions of pBR322/HPV16 
plasmid ranging from 1.0 x 10"“ to 1.0 x 10" . Primers HPV16-1 and 
4, 1 and 2, and 3 and 4 were used to produce the E6E7, E6 and E7 
products as shown. KB standard is at far right. 
# 
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(Figure 4) PCR Results. HPV-X6 E6 amplification of patient 
specimens using primers HPV16-1 and HPV16-2. Band corresponding to 
approximately 183 base pairs can be clearly seen at level of the 
arrow. 
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(b) 
(Figure 5a and b) Restriction Digests. In (a) specimens cut with 
type 16 specific enzyme, TaqI. Remnants of uncut form are present 
at higher molecular weight. Cut form is visible as lower band. In 
(b) , digested with a type 18 specific enzyme, Hae III, all the 
specimens remained in uncut form. There were no visible bands of 
lower molecular weight. 
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(Figure 6) Serial dilutions with labelled white blood cells 
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(Figure 7) Probes for specimen adequacy. Original ViraPap filters 
were stripped and reprobed with random labelled human genomic 
probe. Filter #1 is at top, and filter #2 at the bottom. 
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